Gallbladder surgery : novel insights into treatment of benign and malignant diseases, complications, and treatment outcomes by Koppatz, Hanna
Department of Gastrointestinal Surgery, Abdominal Centre 
Helsinki University Hospital 
Doctoral Programme in Clinical Research 
Faculty of Medicine 






Gallbladder surgery – novel insights 
into treatment of benign and 
malignant diseases, complications, 




















To be presented for public discussion with the permission of the Faculty of 
Medicine of the University of Helsinki, in Auditorium 2, Biomedicum, University Meilahti 





Adjunct professor Ville Sallinen M.D., Ph.D. 
Department of Liver and Transplantation Surgery 
Department of Gastrointestinal Surgery  
Helsinki University Hospital 
Helsinki, Finland 
Adjunct professor Tom Scheinin M.D., Ph.D. 
Department of Gastrointestinal Surgery 
Helsinki University Hospital 
Helsinki, Finland 
Reviewers 
Adjunct professor Jukka Karvonen M.D., Ph.D. 
Department of Gastrointestinal Surgery 
Turku University Hospital 
Turku, Finland 
Adjunct professor Joonas Kauppila M.D., Ph.D. 
Department of Surgery 





The Faculty of Medicine uses the Urkund system (plagiarism recognition) 






Professor Kjetil Søreide, M.D., Ph.D. 
Department of Gastrointestinal Surgery 
Stavanger University Hospital, 
Stavanger, Norway




























               To Niklas, Ida and Emilia  
 4 
CONTENTS 
Abstract …………………………………………………………………………. 6 
Tiivistelmä ……………………………………………………………………… 8 
List of original publications ……………………………………………… 11 
Abbreviations …………………………………………………………………. 12 
1 Introduction ……………………………………………………………... 13 
2 Review of the literature ………………………………………………. 15 
2.1 Gallbladder ………………………………………………………………………… 15 
2.1.1 Anatomy of the extrahepatic ducts and gallbladder …………… 15 
2.1.2 Gallbladder histology ……………………………………………………… 17 
2.2 Benign gallbladder findings ………………………………………………….. 17 
2.2.1 Cholesterolosis and adenomyomatosis ……………………………... 18 
2.2.2 Cholecystolithiasis ………………………………………………………….. 18 
2.2.3 Cholecystitis ………………………………………………………………….. 19 
2.2.3.1 Acute cholecystitis …………………………………………………… 19 
2.2.3.2 Chronic cholecystitis …………………………………………………. 20 
2.2.4 Mucosal polyps ………………………………………………………………. 20 
2.3 Gallbladder surgery …………………………………………………………….. 21 
2.3.1 Open cholecystectomy ……………………………………………………. 21 
2.3.2 Laparoscopic cholecystectomy ………………………………………… 21 
2.3.2.1 Laparoscopic instrumentation ……………………………………. 25 
2.3.2.2 Complications of laparoscopic cholecystectomy …………... 28 
2.3.3 Surgical reconstruction after biliary complication …………….. 31 
2.4 Management of gallbladder malignancy ………………………………… 34 
2.4.1 Premalignant findings …………………………………………………..... 34 
2.4.2 Gallbladder carcinoma ………………………………………………….... 34 
2.4.2.1 Epidemiology and diagnosis ………………………………………. 36 
2.4.2.2 Surgical treatment …………………………………………………….. 40 
2.4.2.3 Oncologic treatment ………………………………………………….. 47 
3 Aims of this study …………………………………………................. 48 
4 Material and methods ………………………………………………….. 49 
4.1 Study design and research settings ………………………………….…... 49 
4.2 Patients ……………………………………………………………………............ 49 
4.3 Definitions ………………………………………………………………............. 50 
4.4 Statistical methods ………………………………………………………......... 52 
5 Results ……………………………………………………………………….. 54 
5.1 Comparison of 3D and 2D laparoscopy in cholecystectomy (I)…. 55 
5.2 Biliary tract injuries (II) …………………………………………………....... 55 
 5 
5.2.1 Surgical reconstruction after bile duct injury ……………………. 56 
5.2.2 Quality of life after bile duct injury ………………………………….. 58 
5.3 Necessity of histopathological examination after cholecystectomy 
(III) ................................................................................................ 60 
5.4 Incidence and management of gallbladder malignancy (IV) ……. 61 
6 Discussion …………………………………………………………………. 64 
6.1 Three-dimensional view in laparoscopic cholecystectomy ………. 64 
6.2 Bile duct injury in laparoscopic cholecystectomy …………………… 64 
6.3 Examination of removed gallbladder ………………………………….... 66 
6.4 Management of gallbladder cancer …………………………………….... 67 
6.5 Strengths and limitations ………………………………………………....... 68 
6.6 Future prospects ………………………………………………………............ 69 
7 Conclusions …………………………………………………................. 71 
8 Acknowledgments ………………………………………………………. 72 
9 References …………………………………………………………………. 73 






Background: Laparoscopic cholecystectomy (LCC) is one of the most 
common surgical procedures in Finland and other countries. This 
procedure may be associated with an increased risk of biliary complications 
compared to the open procedure. A three-dimensional (3D) view in 
laparoscopy could reduce complications and shorten the operation time of 
LCC compared to conventional 2D laparoscopy, but there is no previous 
data on this. Since bile duct injury is the most feared complication of LCC, 
the impact on the patient’s quality-of-life (QOL) after LCC complicated by 
biliary injury has been extensively studied. However, little is known about 
the QOL of patients with biliary injury compared to patients who have 
undergone uncomplicated cholecystectomy. On the other hand, it has been 
challenging to assess the success of the reconstructive operations for biliary 
injury without a uniform classification, which has only recently been 
proposed. 
The high number of cholecystectomies also results in a high burden in the 
pathology units since all gallbladder specimens are routinely sent for 
histopathological evaluation. A malignant tumor is rarely found in the 
gallbladder, and therefore a selective histopathologic examination could be 
considered. At present, it is not clear whether the selective histopathologic 
examination would be safe without compromising the patient’s safety, as 
gallbladder cancer (GBC) has poor prognosis. No population-based studies 
are available on changes and GBC treatment outcomes in the Finnish 
population in recent decades. 
 
Material and methods: This thesis consist of four studies. It included 
2600 patients operated on or treated for gallbladder findings in the Helsinki 
University Hospital specific catchment area during 2000–2017.  
The first study was a randomized controlled trial. In this study we explored 
whether the LCC is faster and safer with a 3D rather than a 2D laparoscope 
in the surgery of patients eligible for day surgery. The primary outcome was 
operation time. The second study was a retrospective cohort study including 
patients with a major bile duct injury. QOL was measured with three 
questionnaires (Gastrointestinal quality-of-life, SF-36, and a non-validated 
questionnaire) and compared with patients with an uncomplicated 
cholecystectomy. The outcomes of reconstruction of major bile duct injury 
were evaluated with the newly proposed standards of Cho and Strasberg. 
The third study examined the need for routine histopathologic examination 
of gallbladder removed for benign indication in a retrospective setting. The 
fourth study continued by clarifying the incidence, management, and 
prognosis of diagnosed GBC in a retrospective population-based study. 
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Results: In Study I, 105 and 104 patients were randomly allocated to be 
operated with a 3D or a 2D laparoscope, respectively. The 3D-system did 
not reduce the LCC operation time (3D vs 2D; 49.0 vs 48.0 min, p=0.703). 
The operation time was not shorter if performed by residents (3D vs. 2D; 
62.0 vs. 60.0 min, p=0.596) or attendings (42.5 vs. 42.0 min, p=0.406). The 
3D technique did not affect intraoperative or postoperative complications, 
and no biliary tract complications occurred. Study II included 52 patients 
with a major bile duct injury and 53 patients who had had an uncomplicated 
cholecystectomy as controls. All patients were operated on during 2000–
2016. We found no difference in the long-term (median follow-up 90 
months) QOL between patients with bile duct injury and the controls. Three 
patients (5.8 %) died due to the injury. The ‘primary patency’ rate was 71% 
and the ‘actuarial primary patency’ at 1 and 5 years was 58% and 53%, 
respectively. The patency was achieved in 83% if the primary reconstructive 
operation was performed by a hepatobiliary surgeon. Study III showed that 
GBC is rarely (n=10/2034; 0.5%) found in gallbladders removed for 
primarily benign reasons. Specimen with GBC in the histopathologic 
examination were always macroscopically abnormal (wall thickening, 
tumor, or local hardening). No malignancy was found from macroscopically 
normal gallbladders. In Study IV, we had 294 patients with GBC and 
revealed a low and slightly declining GBC incidence in Southern Finland, 
1.32/100,000 inhabitants during the study period 2006-2017. The number 
of patients proceeding to curative-intent surgery was 19%, and the 
estimated overall 5-year survival was 12%. Neoadjuvant therapy was not 
used, but 21 (40%) patients received adjuvant therapy. If curative-intent 
surgery was performed, the estimated 5-year survival reached 57%, 
otherwise it was 1.3%. 
 
Conclusions: Cholecystectomy is a common and safe procedure when the 
correct surgical technique and the possibility of anatomical variations are 
considered. The use of 3D laparoscopy system does not improve the safety 
or efficacy compared to 2D laparoscopy. If a severe bile duct injury occurs, 
biliary reconstruction is recommended to be performed by a hepatobiliary 
surgeon. Regardless of the success of the biliary reconstruction or the stage 
of achieved patency, the long-term QOL of patients with achieved and 
maintained patency is comparable to that of control patients.  
A gallbladder that is macroscopically normal and removed for benign 
reason, may not need histopathologic examination. A substantial amount of 
health care resources can be saved in adopting a selective histopathologic 
examination after cholecystectomy for benign reason. GBC is a rare 
malignancy with poor prognosis. Increasing the proportion of patients 
undergoing curative-intent resection, as well as initiating neoadjuvant 
therapy and increasing adjuvant therapy could possibly increase the 





Tausta: Laparoskooppinen sappirakonpoisto on yksi yleisimmistä 
kirurgisista toimenpiteistä niin Suomessa kuin muissa maissa. Tähän voi 
liittyä avotoimenpidettä useammin sappitiekomplikaatio. Kolmiulotteinen 
(3D) näkymä laparoskopiassa voisi vähentää komplikaatioita ja lyhentää 
sappirakonpoiston leikkausaikaa verrattuna tavanomaiseen 2D-
laparoskopiaan, mutta näyttöä tästä ei vielä ole. Sappitievaurio on 
mahdollisesti pelätyin sappirakonpoiston komplikaatio, ja sen vaikutusta 
potilaan elämänlaatuun on tutkittu laajasti. Komplikaation kohdanneiden 
ja komplisoitumattoman sappirakonpoiston läpikäyneiden potilaiden 
elämänlaadun eroista tiedetään kuitenkin vähän. Toisaalta on ollut 
haastavaa arvioida sappitievaurion korjauksen onnistumista ilman 
yhtenäistä luokitusta, jota ehdotettiin vasta äskettäin.  
Sappirakonpoistojen suuri määrä johtaa patologian yksiköiden suureen 
kuormaan, kun poistetut sappirakot on tavattu lähettää rutiininomaisesti 
histopatologiseen tutkimukseen. Pahanlaatuinen muutos on löydöksenä 
harvinainen, ja siksi voitaisiin harkita valikoivaa patologista tutkimusta. 
Tällä hetkellä ei ole selvää, olisiko tämä toimintatapa turvallinen eikä 
vaarantaisi potilaan turvallisuutta, sillä sappirakon syövällä on huono 
ennuste. Sappirakon syövän ilmaantuvuuden ja hoitotulosten muutoksista 
Suomen väestössä ei kuitenkaan ole vielä saatavilla väestöpohjaisia 
tutkimuksia viime vuosikymmeninä. 
 
Materiaali ja menetelmät: Tämä väitöskirja koostuu neljästä osatyöstä. 
Potilaita oli kaiken kaikkiaan noin 2600, joita oli hoidettu sappirakon 
löydöksien vuoksi Helsingin ja Uudenmaan sairaanhoitopiirin 
erityisvastuualueen (HYKS-erva) sairaaloissa vuosina 2000-2017. 
Ensimmäinen osatyö oli satunnaistettu kontrolloitu tutkimus. Tässä 
tutkimuksessa selvitimme, olisiko 3D-laparoskooppinen sappirakonpoisto 
nopeampi ja turvallisempi kuin 2D-laparoskoopilla tehty toimenpide 
päiväkirurgisilla potilailla. Päävastemuuttuja oli leikkausaika. Toinen 
tutkimus oli retrospektiivinen kohorttitutkimus, johon osallistuneilla 
potilailla oli todettu vakava sappitievaurio. Elämänlaatua mitattiin 
kyselylomakkein ja verrattiin potilaisiin, joilla sappirakonpoiston 
yhteydessä ei tullut komplikaatiota. Vakavan sappitievaurion korjauksen 
onnistumista arvioitiin Chon ja Strasbergin äskettäin ehdottamien 
standardien mukaisesti. Kolmannessa osatyössä selvitimme sappirakon 
rutiininomaisen histopatologisen tutkimuksen tarvetta, kun sappirakko oli 
poistettu hyvänlaatuisen syyn vuoksi. Neljäs osatyö jatkoi selvittämällä 




Tulokset: Osatyössä I, 105 ja 104 potilasta randomoitiin 3D- ja 2D-
laparoskooppisiin sappirakonpoistoihin. 3D-järjestelmä ei nopeuttanut 
sappirakonpoiston leikkausaikaa (3D vs. 2D; 49,0 vs. 48,0 min, p = 0,703) 
eikä se myöskään lyhentynyt erikoistuvilla (3D vs. 2D; 62,0 vs. 60,0 min, p 
= 0,596) tai erikoislääkäreillä (42,5 vs. 42,0 min, p = 0,406). 3D-tekniikka 
ei vaikuttanut myöskään leikkauksenaikaisiin tai leikkauksen jälkeisiin 
komplikaatioihin, eikä sappitiekomplikaatioita esiintynyt. Osatyöhön II 
otettiin 52 potilasta, joilla oli todettu vakava sappitievaurio. 53 potilasta 
ilman vauriota toimi verrokkeina näille potilaille. Kaikki potilaat oli leikattu 
vuosina 2000–2016. Sappitievauriopotilaiden ja verrokkien välillä ei 
havaittu eroa pitkäaikaisessa (mediaaniseuranta-aika 90 kuukautta) 
elämänlaadussa. Kolme potilasta (5,8 %) kuoli sappitievaurion vuoksi. 
”Primary patency”, sappiteiden aukipysyvyyden aste, oli 71 %. Yhden ja 
viiden vuoden kohdalla ”Actuarial primary patency rate” oli 58 % ja 53 %. 
Avoimuus saavutettiin 83 %:lla, jos ensisijaisen korjausleikkauksen suoritti 
maksakirurgi. Osatyö III osoitti, että sappirakon syöpää esiintyy harvoin (n 
= 10/2034; 0,5 %) sappirakoissa, jotka poistetaan hyvänlaatuisista syistä. 
Sappirakko, josta syöpä löytyi, oli aina makroskooppisesti poikkeavaa 
(seinämän paksuuntuminen, kasvain tai paikallinen kovettuminen). 
Makroskooppisesti normaaleista sappirakoista ei löytynyt 
pahanlaatuisuutta. Osatyössä IV löysimme 294 syöpäpotilasta ja 
paljastimme matalan ja hieman laskevan sappirakon syövän 
ilmaantuvuuden Etelä-Suomessa, 1,32/100 000 asukasta tutkimusjaksolla 
2006–2017. Kuratiivistavoitteiseen leikkaukseen päätyneiden potilaiden 
osuus oli 19 %, ja arvioitu 5 vuoden kokonaiselossaoloaika 12 %. 
Neoadjuvanttihoitoa ei käytetty, mutta 21 (40 %) potilasta sai 
adjuvanttihoitoa. Kuratiivistavoitteisen leikkauksen jälkeen viiden vuoden 
eloonjääminen oli 57 %, mutta muuten se oli 1,3 %. 
 
Johtopäätökset: Sappirakonpoisto on tavallinen ja turvallinen 
toimenpide, kun huomioidaan oikea kirurginen tekniikka ja anatomisten 
vaihtelujen mahdollisuus. 3D-tekniikan käyttö ei kuitenkaan paranna 
sappirakonpoiston turvallisuutta tai tehokkuutta 2D-laparoskopiaan 
verrattuna. Vakavan sappitievaurion ilmaantuessa, maksakirurgin tulisi 
suorittaa korjaustoimenpide. Riippumatta kuitenkaan korjaustoimenpiteen 
onnistumisesta tai korjauksen jälkeisen sappiteiden auki pysyvyyden 
asteesta, potilaiden pitkäaikainen elämänlaatu on samanlainen kuin 
kontrollipotilailla. 
Makroskooppisesti normaali ja hyvänlaatuisista syistä poistettu sappirakko 
ei tarvinne histopatologista tutkimusta. Ottamalla käyttöön selektiivinen 
histopatologinen tutkimus hyvänlaatuisista syistä poistetuissa 
sappirakkonäytteissä, voitaisiin säästää huomattava määrä 
terveydenhuollon resursseja. Sappirakon syöpä on harvinainen, mutta sen 
ennuste on huono. Ei pelkästään lisäämällä kuratiivistavoitteisten 
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leikkausten määrää, vaan myös neoadjuvanttihoidon käytöllä ja lisäämällä 
adjuvanttihoitoa saavien potilaiden määrää, voitaisiin todennäköisesti 
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Gallstone disease is common in the Western population, with a 9-21 % 
prevalence (1). Annually, 9000, 76000, and 370000 cholecystectomies, the 
most common treatment for gallbladder disease, are performed in Finland, 
the United Kingdom, and the United States, respectively, making it one of 
the most common abdominal surgical procedure (2-4).  
Upper right abdomen pain is an unspecific symptom caused by various 
reasons. Postprandial right upper abdominal pain with or without elevation 
of liver transaminases hints at symptomatic stones in the gallbladder or bile 
ducts (5). Acute jaundice with pain is more likely to be a benign disease than 
malignancy (5-7). In other words, with different combinations of different 
symptoms, benign or malignant disease can be suspected. Radiological 
investigations, such as ultrasound, have an essential role in diagnosing the 
stone disease and the cause of pain in the right upper quadrant of the 
abdomen. 
Laparoscopic cholecystectomy (LCC) was developed four decades ago and 
after harsh criticism against mini-invasive surgery (MIS) in the mid-1980s, 
it was accepted as a gold standard when treating symptomatic gallstone 
disease (8). It does not carry high risks, and provides a short recovery time 
for the patient. Later, the safety, efficacy, and patient friendliness has been 
proven in many other procedures as well (9). Today, 3D laparoscopic 
instruments are increasingly available and have been rapidly introduced in 
operating rooms, but possible benefits of these are still somewhat unclear. 
Thus, more detailed knowledge of the benefits of 3D laparoscopy in specific 
procedures could help direct the proper use of resources. 
Compared to the open technique, LCC is thought to have a somewhat higher 
risk of unintentional bile duct injury (BDI). However, after introducing the 
first LCC, the standardized technique and use of the critical view of safety 
(CVS) have decreased the risk of BDI (10). Complications may have a 
significant impact on the patient's quality-of-life (QOL). Any complication 
after medical treatment or surgery affects the patient's QOL, but the severity 
of the complication has only a small effect on the level of QOL impairment 
(11, 12). Notable is that even after a major complication, the QOL is likely to 
return in the long-term follow-up (11).  
The indication for LCC is predominantly benign, symptomatic gallstone 
disease. The wall of the gallbladder specimen in these circumstances is 
mainly macroscopically normal, but the possibility of a routine 
histopathologic examination (HPE) of the specimen has still not been 
Introduction
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abandoned. The reason for this routine action is the possibility of finding 
incidental gallbladder cancer (iGBC) (13, 14), though this has a low (0.5 %) 
incidence in Western countries in patients operated on for primarily benign 
gallbladder disease. iGBC is often found at an early stage, which improves 
the otherwise poor prognosis (15). Therefore, routine HPE has been 
justified in many centers (13, 16). Nevertheless, the incidence of gallbladder 
cancer (GBC) being low, more selective HPE could save millions of Euro’s 
(17, 18).  
This work investigated cholecystectomy from the perspective of diagnosis 
and treatment of complications and malignant findings. In the literature 
review, the surgically essential anatomy and pathologically meaningful 
structures are also described before diving further into the topics above. 
Treatment of gallstone related diseases such as symptomatic cholelithiasis, 
cholecystitis, pancreatitis, bile duct stones, and GBC creates a significant 
economic burden (19). This burden has escalated, (e.g., an increasing 
number of patients with gallstone disease and operations) partly due to 
advances in surgical techniques (1, 20-22). Owing to the high incidence of 
gallbladder operations, there is much to gain with even minor changes and 
optimizations. Finding the patients who would benefit from 
cholecystectomy, using the right surgical techniques and equipment, and 
centralizing the treatment in the event of complications or GBC can improve 
resource utilization, patient satisfaction, and increase the likelihood of 
survival in severe gallbladder surgery and gallbladder-related disease. 
IntroductionIntroduction
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2 REVIEW OF THE LITERATURE 
2.1 GALLBLADDER 
The gallbladder is a pear-shaped organ on the liver's inferior surface, 
located in the gallbladder fossa beside segments IVB and V of the liver 
(Figure 1). In the early weeks of gestation, the precursor of the extrahepatic 
biliary tree develops from the foregut. The gallbladder forms then from the 
precursor of the bile duct by dilating (23). The primary function of the 
gallbladder is to store bile. Bile is continuously produced in the liver and 
either stored in the gallbladder or drained into the small bowel. The bile 
salts of the bile are absorbed in the intestine back into the bloodstream and 
return to the liver in the enterohepatic circulation (24). 
2.1.1 Anatomy of the extrahepatic ducts and gallbladder 
The extrahepatic ducts arising from the foregut constantly maintain the 
contact with the intrahepatic ducts developing from the hepatic 
diverticulum. Via this relationship, a patent lumen between the intra- and 
extrahepatic biliary tree is achieved. Thus, the right and left hepatic duct, 
descending from the liver, appear at the liver hilum to combine into the 
common hepatic duct (CHD). After passing the joining cystic duct (CD), 
they form the common bile duct (CBD), or choledochus. Then the bile drains 
into the duodenum through the ampulla of Vater (sphincter of Oddi). Bile 
forms in the liver cells, from where it is secreted into the bile ducts. The 
gallbladder stores the bile if it is not secreted into the bowel. Further, some 
of the bile ducts may drain straight into the gallbladder through its bed. 
These ducts are called the ducts of Luschka (24, 25). 
The gallbladder has four regions: fundus, corpus, infundibulum and neck. 
Additionally, the Hartmann pouch is a small bulge of the infundibulum and 
does not exist in all gallbladders. The gallbladder is 6–10 cm long and 3–4 
cm wide. Lying in close proximity to the liver, the gallbladder is in contact 
with the liver bed via only loose connective tissue (adventitia) with no 
serosa. However, the serosa and the peritoneum coats the surface of the 
gallbladder that is not in contact with the liver. There, the peritoneum 
continues to cover the liver and the abdominal cavity. The arterial blood 
supply arises from the common hepatic artery, which divides into the right 
hepatic artery and further divides to the cystic artery. Venous blood, 
however, goes through small veins to the portal vein (24). 
Multiple variations of the vascular system and biliary tract anatomy exist 
(26). Indeed, an accessory bile duct, single or complex, is found in 16% of 
patients, an aberrant right hepatic artery in 18% and in 14% a doubled cystic 
artery is present (27). A review including over 9000 radiologic or surgical 
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cases revealed that almost 20% of cystic arteries were not found in the 
hepatobiliary triangle (detailed in section 2.3.2) (28). The most common 
biliary abnormalities found from a small cohort were short CD, left-sided 
insertion or insertion of the CD into the right hepatic duct, duct of Luschka 
or accessory hepatic duct (29).  



























2.1.2 Gallbladder histology 
 
The normal thickness of an uninflamed gallbladder wall is 1–3 mm. It 
consists of three layers; mucosa, muscle layer, and serosa/adventitia 
(Figure 2). The highly folded mucosa is lined with a single columnar cell 
layer, which then forms mucosal crypts between those folds (25). Glandular 
structures of the epithelium vary between different parts of the gallbladder; 
the neck encompasses mucous glands, but antral-type metaplastic glands 
are found from other parts (30). Under the epithelium lies the lamina 
propria with loose connective tissue structures, lymphatic channels, blood 
vessels, and nerves (25). 
 
The smooth muscle is organized into an irregular layer of muscle fiber 
bundles. They travel in different directions, sometimes even reaching the 
lamina propria. Epithelia, in turn, may herniate into the muscle layer or 
further beneath, as Rokitansky-Aschoff sinuses, which are presented later. 
Under this smooth muscle layer is the perimuscular loose connective tissue 
called adventitia on the liver side. This layer is the only structure that 
separates the gallbladder from the liver tissue. On the opposite wall, the 
















Figure 2. Gallbladder wall on the liver side 
 
 
2.2  BENIGN GALLBLADDER FINDINGS 
 
The most frequent abnormal radiological finding of the gallbladder are 
gallstones. However, there are also many other clinically relevant findings 
suspected or diagnosed radiologically. Gallbladder wall thickening is not 
only seen in GBC, but also in many benign circumstances. GBC is described 
in section 2.4.  
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2.2.1 Cholesterolosis and adenomyomatosis 
Cholesterolosis, a frequent finding of the gallbladder, is a focal or general 
yellowish deposition on the gallbladder wall consisting of triglycerides and 
cholesterol esters (32). Cholesterolosis can be seen macroscopically after 
cholecystectomy, as well as radiologically as a polypoid lesion. It is an 
incidental finding with no association to clinical outcomes such as high 
serum cholesterol, pancreatitis, or GBC (33). 
Adenomyomatosis (ADM) is a benign finding of the gallbladder wall 
occasionally difficult to distinguish from malignant lesions (32, 34). 
Histologically, it appears as hyperplasia of the mucosa and muscularis 
propria, which can be segmental, fundal, or rarely a diffuse type (34, 35). In 
distinguishing ADM from GBC, it is crucial to see the Rokitansky–Aschoff 
sinuses (tubular excavations through the muscle layer) in otherwise focal or 
generalized wall thickening (32). Asymptomatic ADM, when diagnosed with 
certainty, does not need to be operated on. On the other hand, ADM may 
also be symptomatic or appear as acalculous cholecystitis, indicating 
cholecystectomy (34). 
2.2.2 Cholecystolithiasis 
Cholecystolithiasis is a common phenomenon where the clinical 
presentation of the gallstone disease varies from asymptomatic to different 
complications caused by these stones. Gallstone disease is profoundly 
associated with dietary factors and is related to disturbances in 
enterohepatic circulation (36). Obesity with increased hepatic cholesterol 
secretion increases the risk of gallstones and is more common in women 
than men. In the Western world, stones are mostly composed of cholesterol 
and slightly mixed with calcium, whereas bile pigment stones predominate 
in East Asia (32, 37).   
Symptomatic gallstone disease is classically manifested by postprandial 
abdominal colic at the right upper quadrant, especially triggered by fatty or 
heavy meals. Nausea and vomiting may be involved. In complicated 
gallstone disease, the stones can cause biliary obstruction, cholangitis or 
pancreatitis by emerging into the CBD. In Mirizzi’s syndrome, a gallstone 
impacts the cystic duct causing compression to adjacent structures and 
finally leads to a fistula of the CHD or CBD. Stones are also associated with 
cholecystitis and further gallbladder abscess and perforation (32). In 
Swedish and Danish population-based studies, gallstones were associated 
with cholangiocarcinomas, but the risk decreased a few years after 
cholecystectomy (38, 39). One could speculate whether this is related to the 
formation of stones due to disturbed bile flow, which is still caused by 
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obstruction in the bile duct caused by carcinoma. Further, large stones are 
associated with GBC (40, 41). 
 
The first-choice treatment for symptomatic cholecystolithiasis is 
laparoscopic cholecystectomy. If a patient is not suitable or does not consent 
for surgery, they can be offered either oral dissolution therapy or 
extracorporeal shock wave lithotripsy (ESWL) (7). Oral litholysis is possible 
with ursodeoxycholic acid for patients with small diameter cholesterol 
stones (42). Due to the long duration of treatment, only moderate 
dissolution of the stones and possible complications, these non-surgical 
treatments are not widely used (7). 
 
2.2.3 Cholecystitis  
 
In inflammation of the gallbladder, the clinical presentation is seen as a 
thickening of the gallbladder wall in the radiological imaging. Histologically 
the presentation between chronic and acute cholecystitis differ.   
 
2.2.3.1 Acute cholecystitis 
 
In acute cholecystitis, the patient may have, unlike in bile colic, constant 
pain in the right upper abdominal quadrant, and elevated serum C-reactive 
protein and leukocyte levels. Fever, nausea and vomiting may also occur. 
The diagnosis is confirmed with abdominal ultrasonography (US) showing 
pericholecystic edema and gallbladder wall thickening.  
 
Acute cholecystitis is often caused by an obstruction of the gallbladder neck 
or the cystic duct. Then the intraluminal pressure gradually increases and 
results in an inflammation of the gallbladder wall (37, 43-45). However, 
since acalculous cholecystitis also occurs in about 4 % of acute cholecystitis, 
factors other than stones are involved as well. Indeed, acute acalculous 
cholecystitis is most common in patients in intensive care units (46). If the 
inflammation proceeds further, the wall turns gangrenous and may 
perforate. This may appear especially in elderly or diabetic patients and in 
acalculous cholecystitis. Emphysematous cholecystitis, caused by gas-
forming bacteria such as Escherichia coli, Clostridium perfringens or 
welchii, is also a severe disease (47). This is diagnosed with a computed 
tomography (CT) scan, which reveals air in the gallbladder wall. Clinically, 
these patients are critically ill. They may need vasoactive medication and 
other supportive treatment. After surgical treatment, morbidity and even 
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2.2.3.2 Chronic cholecystitis 
Chronic cholecystitis is highly (95%) associated with cholelithiasis. In this 
condition, intraluminal stones cause recurrent mucosal irritation and 
microtrauma to the gallbladder wall (37, 45). Histologically, atrophic or 
ulcerated mucosa, smooth muscle hypertrophy, lymphoid infiltration and 
Rokitansky–Aschoff sinuses, due to continuous intraluminal pressure, may 
be seen (50). A chronically inflamed gallbladder may be rudimentarily 
atrophied and covered with adhesions, hence raising the risks of the surgical 
procedure. 
Xanthogranulomatous cholecystitis (XGC) is a rare variant of chronic 
cholecystitis. It is highly associated with cholelithiasis and obstruction of 
the gallbladder. Though benign, the XGC strongly mimics GBC in a 
preoperative CT scan (51-53). It appears in approximately 1.5–5% of all 
gallbladder specimens (51, 54). XGC is diagnosed by specific 
histopathologic findings with giant foamy macrophages and proliferative 
fibrosis (54). 
2.2.4 Mucosal polyps 
Gallbladder polyps are normally asymptomatic mucosal extensions 
detected incidentally by ultrasound or CT (55). They may appear as single 
(62 %) or multiples and vary in size. Polyps are usually either pseudo-polyps 
or cholelithiasis; true polyps are rare (56, 57). Larger polyps with a size over 
ten millimeters are associated with gallbladder malignancy, particularly 
common in elderly patient (58, 59). Current practices suggest that 
asymptomatic polyps larger than ten millimeters should be removed by 
cholecystectomy (59), but an even higher (12 mm) cut-off point has been 
proposed for young and asymptomatic patients (60). Polyps between five 
and ten millimeters should be surveilled, but polyps smaller than five 
millimeter do not need any follow-up (59). Patients with primary sclerosing 
cholangitis (PSC) are an exception, since their lifetime risk of GBC is 
elevated around 2 %. Therefore, annual surveillance of the gallbladder to 
reveal any findings is recommended (61).  
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2.3  GALLBLADDER SURGERY  
 
Symptomatic gallstone disease is the most common indication for 
gallbladder surgery.   
 
2.3.1 Open cholecystectomy 
 
The laparoscopic technique, discussed in the next section, established its 
place in the early 1990s. Before that, open cholecystectomy was the 
standard procedure to manage gallbladder diseases. In this procedure, the 
surgeon performs a Kocher (subcostal) or an upper middle-line incision 
with the patient under general anesthesia. The gallbladder is exposed from 
under the liver and removed from the liver bed (62).   
 
Today, the direct open approach is somewhat rare and primarily used if 
laparoscopy is contraindicated (for instance for patients with multiple 
comorbidities or critically ill patients) or difficult to perform (63, 64). 
Additionally, the direct open approach may be used in open procedures 
primarily for other indications but when the gallbladder requires removal. 
On the other hand, following explorative laparoscopy in preoperatively 
known cases with gallbladder malignancy, an open cholecystectomy is used 
to perform curative intent resection (65). Mortality after open 
cholecystectomy is low (0.17–0.85%) and it is highly associated with the 
patients’ age, the urgency level of gallbladder surgery, and the disease (66, 
67). 
 
If a safe laparoscopic approach does not seem possible, the conversion to 
open must be considered (68). In two statewide surveys from the UK and 
USA, the conversion rate was expectedly higher in emergency cases (9.4–
17.5%) than in elective surgery (4.6–9.1%). Still, when considering 
morbidity and mortality, the LCC is safe in emergency cases as well (63, 69). 
The laparoscopic procedure is more likely converted to open when the 
patient is male, older, or if the gallstone disease is complicated and mainly 
due to difficult circumstances (69, 70). In elective operations, adhesions are 
a common indication for conversion (71). Other bail-out procedures 
managing difficult LCCs are described in the next section. 
 
2.3.2 Laparoscopic cholecystectomy 
 
Introducing the first LCC was an essential step in the rise of MIS (72). The 
laparoscopic technique for gallbladder surgery was introduced for the first 
time by the German surgeon Erich Mühe in 1985 using a single port 
technique (8, 73). However, the French physician Phillip Mouret in 1987, 
brought a video-laparoscope into the procedure, thus developing the 
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modern LCC technique (74). The advantages of the laparoscopic approach 
were quickly approved, and laparoscopy displaced the open technique.    
At present, LCC is the method of choice for gallbladder surgery for 
cholecystolithiasis and its complications when the equipment and 
knowledge of MIS procedures in the operating unit are adequate (7). 
Symptomatic cholecystolithiasis is the main indication for LCC. Other 
indications are acute cholecystitis, gallbladder polyps, or otherwise 
complicated stone disease (e.g., pancreatitis, ductal stones). For patients 
without any symptoms, LCC may be recommended when stones are large, 
or the follow-up for the lesion (e.g., polyp) of the gallbladder wall cannot be 
adequately controlled by imaging studies (7). 
In LCC, a few anatomical landmarks, such as Rouviere's sulcus and the base 
of liver segment four, should be used to find the safest plane for surgery (75, 
76). The presentation of Rouviere’s sulcus (incisura hepatis dextra, Gans 
incisura) varies. However, it is visible in 90% of patients as a scar, slit, or 
deep sulcus showing the plane of the CBD (77). All surgical approaches 
should stay above these imaginary lines connecting the base of liver segment 
four and Rouviere's sulcus (75, 78). Regardless of laparoscopic 
instrumentation used, it is mandatory to identify the “CVS” (10, 79). The 
CVS is a view where the triangle of Calot (cystohepatic triangle) is prepared. 
Moreover, the liver bed and only two structures (cystic duct and artery) 
ascending to the gallbladder are visible (Figure 3). Gaining the CVS 
minimizes the risk of bile duct or arterial complications but does not remove 
the possibility of them completely (10).  
On the other hand, in difficult circumstances if the CVS is not achievable, 
the fundus-first technique and subtotal cholecystectomy can be used as bail-
out procedures in addition to open conversion (80). In the fundus-first 
technique, the preparation starts from the fundus and proceeds with 
retrograde dissection. This proceeds until the safe preparation line 
disappears. Some studies have showed a connection with the fundus-first 
technique and major venous and bile duct injuries (81). Keeping this in 
mind, the dissection plane is held close to the gallbladder. Combining the 
fundus-first technique with subtotal cholecystectomy might offer a safe 
approach for cholecystectomy without need of conversion. Depending on 
the surgeon’s experience, an appropriate technique to avoid BDI is chosen. 
It is also possible to try to avoid a BDI by using intraoperative imaging. This 
includes cholangiography, intraoperative US, and fluorescence 
cholangiography. In cholangiography, a small tube is inserted into the bile 
duct to obtain a radiographic view of the biliary tree filled with contrast 
agent (Figure 4). A Swedish study found a BDI risk reduction when 
cholangiography was used in patients with a history of an acute cholecystitis 
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or a concurrent cholecystitis (82). In fluorescence cholangiography, the 
contrast agent (fluorescing indocyanine green) is infused into a vein to 
illuminate the biliary system. An intraoperative US can visualize other 
structures as well. None of these are shown to be superior, nor do the 
current recommendations elevate one above another. However, some 
centers use these as a current routine during the LCC (76, 78, 83). 
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Figure 4. Cholangiography during LCC. The instrument on the left is 
holding the gallbladder fundus, while other holds the duct where the 
contrast agent was inserted in. No complication appeared, the contrast 
agent also flows upwards and shows the biliary tree.  
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2.3.2.1 Laparoscopic instrumentation 
 
After the first LCC, the four-port laparoscopy became a standard for 
cholecystectomy (83). Beyond this standard, other LCC techniques have 
been developed and studied to improve results in cosmesis and 
painlessness. These techniques include the robotic, the natural orifice 
transluminal cholecystectomies, and the use of only 1–3 ports (84-86). 
However, the long learning curve has reduced the popularity of these 
techniques. Further, as the number of ports decreases, the possibility of 
traction and counter-traction, necessary for optimal surgery, is reduced and 
achieving a safe view may be challenging (83). On the other hand, the 
surgeons experienced workload during the operation, operation length, and 
thus costs of surgery may increase (87).  
 
In the initial laparoscopic technique, four laparoscopy ports were used (8). 
First, a supraumbilical incision is made. Second, a pneumoperitoneum is 
performed after inserting a trocar openly or in direct visual control using an 
optical trocar. A Verres needle may also be used for insufflation. The other 
trocars are then inserted in direct visual control into subxiphoid, right 
subcostal midclavicular, and anterior axillary line positions (88-90). The 
operating surgeon stands either on the patient’s left side or between the 
patient’s legs, while the assistant is on the patient’s left side. A video monitor 
is on the patient’s right side facing toward the surgeon. 
 
The benefits of LCC are unquestionable. Despite this fact, the operation in 
the 3D field with the two-dimensional (2D) view is challenging. The 
phenomenon called stereopsis, or stereo vision, is possible for humans 
having two eyes facing forward. The differences between two forward-
looking retinas that deliver slightly different images to the brain are 
processed to develop an experience of stereoscopic view. The English 
physicist Charles Wheatstone first described this in 1838, when he first 
introduced the simple stereoscope (91). This stereoscopic vision is, however, 
lost with a 2D videoscope. Therefore, it demands that the surgeon 
understands the 3D space from a 2D screen, hence increasing the risk of 
misperception and complications. 
 
The 3D laparoscopic system was introduced to improve results, reduce 
errors and shorten the learning curve of MIS (92). With the 2D view, the 
surgeon uses cues such as relative sizes of structures, shadows, and 
interposition to build a 3D picture (93). However, the 3D optic is a dual-
channel scope connected to two cameras, which deliver two different views 
to display on a monitor. This blurred picture on the screen can be seen as a 
3D-picture when viewed through polarized 3D glasses (94). Previous 3D 
glasses were heavy, causing headaches, dizziness, and nausea to the 
operating surgeon (95). Subsequently, 3D equipment, including 3D glasses,  
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scopes, and monitors, have evolved, and the surgery experience is now 
pleasant (96, 97). 
The 3D technique has been shown to improve the movement accuracy, 
speed, and learning curve in several non-clinical studies (98-102). The 3D 
equipment is even preferable to use in training since skills acquired with 
3D-simulation are also transferable to the 2D environment (97, 99). 
However, 10% of people lack adequate stereoacuity (103). In the absence of 
this stereoscopic view, or when significantly reduced, the individual will not 
be able to take advantage of 3D technology (104). 
In 1998, Hanna et al. studied how the use of a 3D-camera would impact 
LCC. Findings from this prospective research were not encouraging as they 
reported on the technical flaws of the 3D monitor and the increased visual 
strain caused by this technology (95). Given the advances in technology, it 
is understandable that similar problems do not occur in current 3D 
laparoscopy compared to a few decades ago. Since then, a few studies have 
demonstrated the benefits of 3D technology in laparoscopy (105, 106). 
However, the benefits of 3D technology are mainly limited to operations 
requiring exact depth vision, such as laparoscopic suturing (107-110). 
Therefore, a panel of European surgeons only made a cautious 
recommendation on the use of 3D technology in surgery (108). All available 
studies considering 2D versus 3D laparoscopy in cholecystectomy are 
detailed in Table 1.   
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Table 1. Three-dimensional laparoscopy in cholecystectomy *Article in 
Chinese. Abbreviations: 2D – two-dimensional; 3D – three-dimensional; 
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No difference in 
performance by 
specialist surgeons. In 
complex cases, 3D 
reduced the Calot’s 
triangle dissection 
time. 
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2.3.2.2 Complications of laparoscopic cholecystectomy 
LCC is safe, but as with all surgical procedures, includes potential risks. The 
laparoscopic procedure itself is associated with possible complications such 
as bowel or vascular injury caused by trocar insertion. However, in LCC in 
particular, biliary, liver hilar, or vascular complications cause the primary 
concern. These complications can have a remarkable impact on not only 
expenses of the healthcare system but also on patients mental and physical 
wellbeing. Depending on the degree of biliary complication, the patient may 
need repeated healthcare contacts and procedures to be able to maintain the 
biliary continuity. The impact of BDI to patients’ QOL may be significant, 
which can be seen in short- and long-term follow-up (12, 116, 117). 
The incidence of biliary complications is 0.39–1.1% (118-121), including a 
major BDI in 0.16–0.43% of cases (119, 120, 122). A vascular component is 
present in 5.1% of patients treated for BDI (123). The reason for 
complications in LCC is mainly surgeon’s misperception, but several other 
reasons (inflammation and adhesions, Mirizzi’s syndrome, hemorrhage) 
also exist. The use of scissors or clips on the wrong structures and the use of 
thermal instruments in direct proximity to vascular or main biliary 
structures are the primary mechanisms of BDI (10, 81, 124, 125).  
Various classifications have been produced to depict the severity of the bile 
tract injuries. Some of them describe only injuries considering bile ducts 
(Bismuth, Strasberg, Amsterdam), while some take into account blood 
vessels (Steward-Way) and the functionality of the biliary tract (Hannover, 
ATOM-classification) (79, 126-129). The Bismuth classification was an 
initial way to illustrate complications but included only defects of the main 
bile duct (127). After that, the Strasberg classification combines the minor 
and severe biliary complications (Table 2) (79). Recently, Cho and Strasberg 
formed a new classification based on the Strasberg classification but 
combined complications A-E into grades 1-3 based on the severity of the 
injury (Figure 5) (Cho 2018). The functional Amsterdam classification 
serves as a proper tool for endoscopist purposes (121). However, a group of 
surgeons of the European Association for Endoscopic Surgeons built a 
classification to comprise all of the BDI classifications found (130). We 
concentrate on major biliary injuries and use the Strasberg and the Cho-
Strasberg classifications in this thesis (Table 2; Figure 5). 
Anatomical variations are common in the biliary tree and its vascularity. 
These variations are involved in 30% of complications during 
cholecystectomy (29). Some of the most typical anomalous structures can 
be recognized. About 10–15% of patients have a superficial middle hepatic 
vein in the liver bed (131). Damage to this can result in severe bleeding. 
However, keeping the dissection plane superficial to the liver bed and close 
Review of the literature
 29 
to the bladder, the injury can be avoided (132). In both open and 
laparoscopic procedures in highly inflamed cases, challenging vasculo-
biliary injuries can be associated with the fundus-first technique (81). 
 
The overall mortality 90-days after cholecystectomy is low, 0.15–0.64%. 
Patients with high age, emergency surgery, or intraoperative complications 
are at higher risk for death (67, 133). However, the laparoscopic approach 
per se does not increase the risk of mortality (134). Indeed, the risk of death 
is three times higher in open cholecystectomy than in LCC (133, 135, 136). 
Nevertheless, the patient’s comorbidity and complexity of the gallbladder 
disease is likely to explain this higher risk.   
 
 
Table 2. Strasberg classification system. Abbreviations: CBD – common 
bile duct   
  
Type  Criteria 
A  Bile leak from cystic duct or liver bed  
B  Partial occlusion of the biliary tree, most frequently from an 
aberrant right hepatic duct 
C  Bile leak from duct (aberrant right hepatic duct) that is not 
communicating with the CBD 
D  Lateral injury of the biliary system, without loss of continuity 
E  Circumferential injury of the biliary tree with loss of 
continuity 
 E1 Transection > 2 cm from the confluence of the hepatic ducts 
 E2 Transection < 2 cm from the confluence of the hepatic ducts 
 E3 Transection involving the confluence of the hepatic ducts with 
continued right and left ductal communication 
 E4 Transection resulting in the destruction of the hepatic 
confluence (and no communication between left and right 
hepatic ducts) 
 E5 Type C injury in the hilum 
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Figure 5. Strasberg classification system illustrated and grouped into 
three grades by Cho and Strasberg.  
Figure 6. BDI diagnosed with endoscopic retrograde cholangiography 
(ERC). Two patients with a blockage at choledochus. A distal choledochus 
is filled with contrast agent, but the proximal part of the biliary tree is not 
visualized.  
A: Elective cholecystectomy for previous 
cholecystitis resulted in E2 type BDI. This 
was diagnosed with ERC where the 
continuity of the choledochus was found 
to be interrupted. A small amount of 
contrast agent spreads in the abdomen. 
B: Difficult BDI (E3) diagnosed with 
ERC after converted cholecystectomy 
for symptomatic cholelithiasis.  
Grade 1 
Grade 3 
Grade 1 Grade 2 
A 
E5 E4 E3 E1/2 
D C B 
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2.3.3 Surgical reconstruction after biliary complication 
 
The need for surgical reconstruction of biliary complications depends on the 
severity of the injury. Most of the complications are minor (Strasberg A–D), 
whit endoscopic or radiologic management being sufficient (119, 121, 137). 
Whether or not the continuity of the biliary tree is lost, is vital for the 
decision of management. Surgical reconstruction is essential after a total 
loss of continuity or a major vessel complication.  
 
Immediate detection of a BDI increases not only the possibility of a 
successful result after definite repair but also improves the QOL of these 
patients (138, 139). The BDI is, however, not detected in about half of these 
operations (140). This oversight increases the risk for severe inflammation, 
need for intensive care, and failure of definitive repair (141). Further, the 
need for repetitive operations leading to reduced working ability and 
prolonged sick leave is a difficult socioeconomic challenge (142). 
 
A hepatobiliary surgeon should perform the surgical reconstruction after a 
major BDI (116, 137, 143, 144). If the support of a specialist is not available, 
abdominal drainage and referral to an adequate hospital is recommended. 
Any inflammation or infection can impair the result of the repair. Therefore, 
an immediate or early repair is preferred (145). On the other hand, time 
itself is not harmful, but inflammation is. Therefore, in cases of acute 
inflammation a reconstruction 4–6 weeks after the complication may be 
justified (143). In a sizeable retrospective multicenter study, which included 
914 patients with BDI, the purpose was to determine optimal timing for 
definitive BDI repair. They did, however, find that the timing of a definitive 
repair was irrelevant to the success of the biliary reconstruction (140). 
 
The goal is to achieve a patent anastomosis between a bile duct and the 
jejunum (Roux-en-Y hepaticojejunostomy or choledochojejunostomy, HJ) 
or distal part of the bile duct (choledochocholedochostomy). The proper 
surgical technique depends on the circumstances and on the biliary injury. 
The principles for the anastomosis performed in surgery are simple: to 
make a patent connection between two tubes with adequate caliber, 
mucosa-to-mucosa, and without tension and vascular impairment (146). 
Circumstances after BDI are mostly not favorable for repair without 
appropriate preparation. The level of injury determines the number of 
anastomoses performed. Both the proximal and distal parts of the bile duct 
are first exposed. The injured part is dissected and removed. Injury at the 
level of the bifurcation might even demand three different anastomoses 
between the jejunum and right, left, and right posterior hepatic duct. 
Otherwise, an anastomosis between the CHD or CBD and CBD or jejunum 
is performed. 
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Either the end-to-side or side-to-side technique (Figure 7) can be used to 
perform the HJ. The latter was presented by the surgeons Hepp and 
Couinaud in 1956, thus the name Hepp–Couinaud technique (147, 148). 
This provided a useful, precise technique for the reconstruction of type E1–
3 biliary injuries, but in E4–5 injuries supplied a method only for left biliary 
duct repair. The use of the side-to-side approach, however, is rationalized 
by providing a wide and well-vascularized anastomosis. However, in the 
case of tiny ducts, when an incision on the side of the duct would more likely 
harm it, this technique is not preferred (149).  
In long-term follow-up, a stricture may evolve in an anastomosis and 
consequently lead to biliary cirrhosis. With an end-to-side HJ, the stricture 
can develop in as many as 30% of patients  (138, 141, 150), but with a side-
to-side reconstruction, the stricture formation decreases to a few percent 
(149, 151). Prophylactic stents are used for preventing stricture formation 
and immediate post-operative complications. However, only if the 
anastomosis is suboptimal, intrahepatic bile duct stones exist, or the bile 
duct is clearly inflamed, is this recommended. Even then, the stenting is 
recommended to only continue for three months (146). The long-term 
success of biliary reconstruction is highly associated with the circumstances 
of the initial operation; absence of abdominal infection, use of correct 
surgical technique and presence of a hepatobiliary surgeon all increase the 
rate of short-term and long-term success of the repair (143, 146).  
Cho and Strasberg (2018) developed a standardized protocol that is also 
used in this thesis to create an opportunity to evaluate and compare the 
results of bile duct repair. By this protocol, the studies described in Table 3 
have evaluated the results of their reconstruction methods. The definitions 
for the terms ‘patency’, ‘primary patency,’ and ‘secondary patency’ are later 
described in section 4.3.  
Figure 7. End-to-side (A) and side-to-side (B) (Hepp–Coinaud technique) 
biliary-enteric anastomosis. 
A B 

































treatment of major 
BDI offers a 
possible choice for 
standard open 
surgery 
35 Robotic 100% 100% (16 months) 
Rueda-de-











this study showed 
better results of 
BDI repair in high-
income countries 
113 Secondary repair/UMIC Open 73%** 
52%* (10 
years) 
122 Primary repair/HIC Open 93% N/A 
Lindemann 








Open NA 89.7%* (10 years) 
Incomplete 
detection of biliary 
tree in the 
preoperative 
evaluation was the 
only predictor of 





Open 92.6% 81.5% (10 years) 
Martinez-




37 Primary repair/LIC Open 89% N/A 
Despite differences 
in referral and 
preoperative and 
operational events, 
good BDI repair 
outcomes can be 
achieved 
41 Primary repair/MIC Open 97% N/A 
 
Table 3. Current studies evaluating bile duct repair with a biliary-enteric 
anastomosis by the proposed standards of Cho and Strasberg (2018) (156). 
*Actuarial secondary patency rate included all patients failed to maintain 
or achieve the primary patency; **Secondary patency rate. Abbreviations: 
BDI – bile duct injury; (U)MIC – (Upper) middle-income country; HIC – 
High-income country; LIC – Low-income country; N/A – not applicable; 
HB – hepatobiliary  
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2.4 MANAGEMENT OF GALLBLADDER 
MALIGNANCY  
2.4.1 Premalignant findings 
Premalignant findings are usually incidental. Two apparent pathways have 
been studied considering precursors for GBC. The evolution of GBC from 
the premalignant cells is not entirely clear because monitoring of an already 
removed gallbladder is not possible. However, histopathological studies 
have revealed “metaplasia-dysplasia-carcinoma” and “adenoma-
carcinoma” sequences (50, 55, 157-159). 
Gallbladder lithiasis, causing constant irritation to the wall, may generate 
epithelial dysplasia. Metaplasia is also a frequent finding in gallbladders 
mutilated by stones. Metaplasia developing to dysplasia is not unequivically 
proven, however, dysplasia and metaplasia are both seen in the immediate 
proximity of cancer cells in these samples (50). The increase of intestinal 
metaplasia and expression of tumor protein p53 is associated with 
chronically inflamed gallbladder specimens with GBC (159). It is estimated 
that a dysplasia would theoretically need ten years to proceed into cancer 
(160).  
Gallbladder adenomas are benign neoplasms of the epithelium. They are 
mainly tubular or less frequently papillary adenomas (158). Adenomas may 
carry a neoplastic potential, although they are rarely precursors of GBC (55, 
157, 161). Patients with a carcinoma originating from an adenoma are older 
than patients with simple adenomas (50). Moreover, the size of these 
malignant polypoid adenomas is over ten millimeters (159). 
2.4.2 Gallbladder carcinoma 
Gallbladder cancer is a rare neoplasia with poor survival. However, it is the 
most frequent biliary tract malignancy (162). In some countries, GBC has 
been the primary cause of death for malignant tumors among women (163, 
164). In Finland, the incidence is approximately 260 new gallbladder and 
biliary tract cancers annually, with the estimated 5-year survival being 14% 
(165). If the GBC occurs on the liver side, the prognosis decreases (166). 
Therefore, the location of the cancer in the gallbladder has also been 
considered in the most recent TNM classification (Table 4) (166, 167).   
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Primary Tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
TiS Carcinoma in situ 
T1 Tumor invades lamina propria or muscular layer 
T1a Tumor invades lamina propria 
T1b Tumor invades muscular layer 
T2 Tumor invades the perimuscular connective tissue on the peritoneal side, without 
involvement of the serosa (visceral peritoneum), or 
Tumor invades the perimuscular connective tissue on the hepatic side, with no 
extension into the liver 
T2a Tumor invades the perimuscular connective tissue on the peritoneal side, without 
involvement of the serosa (visceral peritoneum) 
T2b Tumor invades the perimuscular connective tissue on the hepatic side, with no 
extension into the liver 
T3 Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver 
and/or one other adjacent organ or structure, such as the stomach, duodenum, 
colon, pancreas, omentum, or extrahepatic bile ducts 
T4 Tumor invades the main portal vein or hepatic artery or invades two or more 
extrahepatic organs or structures 
Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastases to nodes along the cystic duct, common bile duct, hepatic artery, 
and/or 
portal vein 
N2 Metastases to periaortic, pericaval, superior mesenteric artery, and/or celiac artery 
lymph nodes 
Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
Anatomic Stage/Prognostic Groups 
Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
IIA T2a N0 M0 
IIB T2b N0 M0 
IIIA T3 N0 M0 
IIIB T1–3 N1 M0 
IVA T4 N0–1 M0 
IVB Any T N2 M0 
IVB Any T Any N M1 
Table 4. American Joint Committee on cancer (AJCC) 8th edition TNM 
staging for GBC (168)  
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Figure 8: Histologic view of gallbladder cancer invading the wall.  
2.4.2.1 Epidemiology and diagnosis 
The incidence of GBC varies between countries, as well as regionally. The 
incidence has been increasing annually in the USA but declining in some 
European countries (169, 170). It is particularly high in India, Pakistan, and 
Ecuador. Somewhat elevated rates of the GBC incidence can be found in 
parts of Europe, female gender being overrepresented in all countries’ GBC 
statistics (171). These neoplastic findings are predominately 
adenocarcinomas (98%). Adenosquamous, squamous, papillary, and 
mucinous subtypes, neuroendocrine tumors, lymphomas, or metastases are 
infrequently detected in the gallbladder specimens (172). Most often GBC 
originates from the gallbladder fundus, producing no symptoms at the early 
stage (173). Jaundice and general symptoms such as fever, nausea, and 
weight loss predict poor survival (174). 
Stone disease is highly associated with the risk of GBC. Indeed, patients with 
gallstones possess a much higher risk of GBC than the average population. 
Still, the risk also varies by genders and ethnicities (171, 175-177). In the 
presence of any polypoid lesion of the gallbladder, the Indian ethnicity itself 
is an independent risk factor for developing GBC (176). Other factors 
increasing the risk of gallbladder malignancy are obesity (178), tobacco 
(179), alcohol (180), number or size of gallstones (181), high age (169), PSC 
(61), and exposure to heavy metal pollution (182). An ultrasound finding of 
porcelain gallbladder (calcified wall of gallbladder) carries an elevated risk 
of GBC. However, porcelain gallbladder itself does not cause GBC, rather a 
long-term inflammation, which causes these calcifying changes of the wall 
(183). This porcelain gallbladder finding was concluded as an indication for 
LCC only for patients with symptoms or clinical suspicion for localized GBC 
(184, 185). 
GBC can be diagnosed preoperatively, during cholecystectomy, or 
incidentally in the histopathologic examination. When discovered 
incidentally, GBC is more often found at an early stage (15, 186, 187). These 
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patients have had symptoms caused by gallbladder stones, which have led 
to gallbladder surgery for a benign indication. An incidental GBC is found 
in 0.2–0.9% of gallbladder specimens and accounts for half of the overall 
GBC cases (14, 15, 186-188). Pre-operative diagnosis is difficult. Early 
cancers especially are frequently misinterpreted as chronic cholecystitis 
upon ultrasound and CT (181). As the GBC progresses further, a mass in the 
gallbladder lumen or infiltrating tumor in the wall appears. A biopsy may 
be taken if the tumor is deemed inoperable. Otherwise, a biopsy is not 
recommended, and the CT provides the basis for diagnosis and the 
possibility of resection (189, 190). 
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2.4.2.2 Surgical treatment 
Surgical resection is the only possible curative treatment for GBC currently 
available. In simple cholecystectomy, only the gallbladder is removed. The 
extended cholecystectomy includes lymph node dissection and liver 
resection (Figure 9). In this, segmentectomy IVb/V, a non-anatomical liver 
resection with 2–3 cm margins (a wedge resection) or hemihepatectomy is 
performed (196, 197).   
Not only does the lymph node status strongly affect the overall survival 
(OS), but also the amount of the dissected lymph nodes (198). Regional 
lymph node dissection includes the hepatoduodenal lymph nodes (197). The 
recommended amount of dissected lymph nodes is at least six (167, 198). 
Thus, the strongest effect on the prognosis of a patient with GBC is achieved 
with 4 to 7 dissected lymph nodes (199). Indeed, an even more extensive 
lymphadenectomy has been proposed. This procedure would include lymph 
nodes from behind the portal vein, posterior pancreatoduodenal, common 
hepatic, and right celiac nodes (200). The importance of lymph node 
dissection is high. It has been proposed that without lymphadenectomy, the 
survival after radical resection would not differ from the simple 
cholecystectomy (201). Besides liver and lymph node resection, a resection 
of the extrahepatic bile duct can be offered for a specific patient group to 
achieve R0 resection. This extended bile duct resection has, however, also 
been seen to increase morbidity (202, 203). An example of a current 
protocol for the management of known or suspected GBC based on an 
American guideline is given in Table 7 (203). The management of GBC is 
based on many different guidelines, and no Finnish guidelines exist so far 
(Table 6). 
For iGBC, cholecystectomy itself can be a curative treatment if the HPE 
reveals in situ carcinoma or a T1a tumor. If the cancer invades through the 
muscle layer (T1b and beyond), further evaluation is needed (203, 204). 
Staging CT is performed to reveal cancer progress. A multidisciplinary 
meeting evaluation is recommended to plan additional procedures (205). If 
the CT scan shows distant lymph node or other metastases, oncologic 
treatment is preferable. However, in the absence of further metastasis or 
other contraindications, the patient can proceed to curative-intent resection 
(Table 6).  
Staging laparoscopy for iGBC starts with an exploration of the abdominal 
cavity (206). If the cancer appears to be disseminated (e.g., to carcinosis), 
though not revealed by CT, the operation is not recommended to be 
continued (189). Recovery after the laparoscopy is faster, which accelerates 
the onset of oncological treatments. Otherwise, the explorative laparoscopy 
is converted to open and proceeds with an appropriate resection. If the 
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cancer has spread to wounds, it is likely to be disseminated. Therefore, a 
port site resection does not improve the prognosis (207). The presence of 
lymphovascular invasion, the stage status, and nodal metastasis decrease 
the success of curative-intent re-resection and survival after incidental GBC 
(208, 209) 
 
Symptomatic GBC is often at the locally advanced (T3–4) stage, nodes are 
involved, or metastasis exists. Therefore, surgical options are mostly 
restricted. The principles of surgical treatment remain the same as in iGBC, 
considering extended cholecystectomy. After a multidisciplinary meeting 
evaluation, and if invasion beyond T1a is not seen, a simple cholecystectomy 
is recommended (196). No clear consensus exists regarding whether a 
simple cholecystectomy would also be sufficient for T1b cancer (196, 210). 
However, even a 3.4-years survival benefit was demonstrated for patients 
with T1b cancer undergoing extended resection compared with a simple 
cholecystectomy (211). After the cancer has advanced to the perimuscular 
connective tissue (T2), the location of the tumor plays a significant role in 
survival (166). The newest AJCC TNM staging was updated in 2017; the 
stage T2 was split to consider whether the growing carcinoma is in a 
peritoneal (T2a) or liver site (T2b) (168). In both cases, current 
recommendations propose an extended cholecystectomy (196, 197, 203, 
212). Surprisingly, a recent study proposed that the hepatic resection might 
not be essential for curative treatment of T2 GBC in T2a or T2b groups (213). 
Beyond this, the current guidelines recommend curative resection for 
patients with nodal involvement until stage T3N1 (196, 203, 212), not 
necessarily excluding a non-metastatic T4N0-1 GBC (197). None of the 
guidelines suggest resection for patients with distal nodal metastases (N2) 
or metastatic (M1) GBC. 
  






   
Figure 9. Hilar lymph nodes and dissection plane of extended 
cholecystectomy.  
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An estimated two-thirds of patients diagnosed with GBC are operated on 
either by cholecystectomy or any level of resection after symptomatic 
disease (214). After iGBC, curative-intent resection is possible in 40–68%, 
which indicates a great variation between centers (15, 202, 215, 216). After 
curative-intent resection, the R0 result improves survival significantly (209, 
217). However, even in one-third of these patients with R0 resection, the 
cancer recurs with loco-regional or distant metastasis (218). Indeed, an 
especially advanced T-stage and the presence of perineural or 
lymphovascular invasion and tumor differentiation increases this risk (199, 
218-220). Since the residual disease is an important factor for predicting the 
outcome after the re-resection, a Gallbladder Cancer Predictive Risk Score 
(GCPS) has been developed (Table 8). Ethun et al. suggested utilizing this 
score for patients with incidentally discovered GBC to predict loco-regional 
residual and distant disease more precisely than T-stage alone (221). Ramos 
et al. found GCPS to adequately identify patients with a high risk of distant 
or regional residual disease, which predicts poor prognosis and could 
thereby guide the decision of re-resection (222). 
 
The management of locally advanced GBC is a widely discussed subject and 
so far without a resolution. A few researchers have studied neoadjuvant 
chemotherapy (NACT) or chemoradiotherapy (NACRT) for patients with 
locally advanced disease or nodal involvement (223-226). Gemcitabine 
alone or combined with platinum was found to stabilize or lead to partial 
response in 77% of patients; 30% proceeded to an attempted resection. 
However, only ten (14%) patients were able to continue to R0 resection 
(225). In another study, patients receiving gemcitabine combined with 
platinum responded better; there, the R0 rate rose to 40% (63 patients) 
(226). Both studies were able to show significantly better OS despite small 
study groups. However, providing a benefit for only a third of patients, the 
routine NACT cannot be recommended for all patients with advanced GBC 
(227). The most recent NCCN guidelines recommend consideration of 
NACT if nodal involvement is present (203). 
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Affiliation Year 
Main purpose of 
this 
recommendation 
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Table 6. Current guidelines for treatment of gallbladder cancer. *No 
recommendation of N1 or M1 statuses. Abbreviations: ESMO – European 
Society for Medical Oncology; GBC – Gallbladder cancer; HPB – hepato-
pancreato-biliary; AHPBA – American Hepato-Pancreato-Biliary 
Association; ASCO – American Society of Clinical Oncology; NCCN – The 
National Comprehensive Cancer Network  
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Current circumstance Key points of management 
Preoperative mass identified • Contrasted CT of chest, abdomen, and pelvis
• Liver function tests and tumor markers
• Consider SL
Incidental finding at surgery • Frozen section of gallbladder if suspicious for
cancer
• Intraoperative staging with resection of any
suspicious
lymph nodes and cystic duct node
• Definitive surgery should be delayed until full
imaging and pathologic workup is complete
• Contrasted CT of chest, abdomen, and pelvis
Incidental findings on pathology • Observation recommended for T1a patients
with R0 resection
• Contrasted CT/MRI of chest, abdomen, and
pelvis for T1b or greater
• Consider SL for T1b or greater
• Consider neoadjuvant therapy in N1 disease
Unresectable (on SL or 
imaging) 
• Biopsy if tissue not available
• Genetic testing
Table 7 Detailed workup of known or suspected gallbladder cancer 
according to NCCN guidelines (203). Abbreviations: CT – computed 
tomography; MRI – magnetic resonance imaging; SL – staging laparoscopy 
Table 8. Gallbladder Cancer Predictive Risk Score (229). Abbreviations: 























TOTAL RISK Loco-regional 
residual 
Distant disease 
Low (3-4) 0% 0% 
Intermediate (5-7) 24% 3% 
High (8-10) 61% 32% 
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2.4.2.3 Oncologic treatment 
 
Some if the guidelines recommend adjuvant therapy with or without radiation 
(CRT) after curative intent resection in both R0 and R1 resections (Table 6) 
(203, 212). The range of regimens available is extensive, and no individual drug 
was superior to others prior to the BILCAP trial (189, 230). According to earlier 
recommendations, adjuvant chemotherapy was mostly based on 
fluoropyrimidine or gemcitabine. The BILCAP trial, however, was a 
multicenter study that found capecitabine to improve the OS by several months 
when treating patients with biliary tract cancer (230). According to ASCO 
Clinical Practice Guidelines, the capecitabine adjuvant chemotherapy is now 
suggested to be offered to all patients with resected biliary tract cancer 
including patients with GBC beyond stage T1b for 6 months (228). The current 
guideline of NCCN suggest an adjuvant CRT for patients with positive nodes or 
R1 resection (203). This treatment with CRT showed a slightly better survival 
advantage when given as adjuvant for patients with T3 or node-positive GBC 
(231, 232). 
 
The strength of adjuvant chemotherapy can be demonstrated especially in 
patients with an advanced stage or nodal involvement (232, 233). 
Chemotherapy, especially with gemcitabine or gemcitabine combined to 
cisplatin, can show this positive effect (164). These cytostatic drugs were first 
discovered to be efficient for biliary tract and pancreatic cancer, but given the 
many similarities between these cancers, they were detected to be valid against 
GBC as well (234, 235). Indeed, adjuvant therapy, also combined with simple 
cholecystectomy, could be beneficial for patients unfit for the most aggressive 
radical curative surgery (233). This can offer a possibility for high-risk patients’ 
care. 
 
If resection is not possible, chemotherapy can provide a survival benefit for 
patients with metastatic or locally advanced, inoperable, GBC. Valle et al. found 
a statistically significant benefit for patients with biliary tract cancer treated 
with gemcitabine/cisplatin compared with gemcitabine alone (236). Dierks et 
al. controlled this protocol for treatment with gemcitabine/cisplatin. They 
found a significant increase in the OS compared to the best supportive care 
(237). However, the number of patients with GBC was low in these studies, 
which concentrated on biliary tract cancers overall.  
 
The advanced and unresectable disease quickly infiltrates the liver or around 
the hepatic duct. Occasionally symptoms emerge after the GBC blocks the 
bowel, but biliary obstruction manifests frequently. As a best supportive care, 
an endoscopist can insert a stent into the obstructed bile duct or bowel (238). 
This treatment offers the patient an open biliary tree and bowel to enable 
possible palliative oncologic treatment. Survival of advanced GBC is poor, and 
with the best supportive care reaches just a few months (173, 239). 
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3 AIMS OF THIS STUDY 
This thesis aims to study laparoscopic cholecystectomy considering the 
safety and feasibility of new technology and surgical complications in 
cholecystectomy. It also aims to study the management of a malignant 
finding of the gallbladder. Specific aims of this study were: 
Study I 
to compare the three-dimensional and two-dimensional laparoscopic 
cholecystectomy, whether the three-dimensional technique is superior 
considering the operation time and safety, 
Study II  
to study the effect of bile duct injury on quality-of-life and report the 
results of biliary reconstructions, 
Study III 
to clarify the need of histopathologic examination of the gallbladder 
specimen after simple cholecystectomy for gallbladder stone disease and 
to report the amount of incidental gallbladder cancers, and 
Study IV 
to determine the incidence, treatment, and survival of gallbladder cancer 
in southern Finland.  
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4 MATERIALS AND METHODS 
 
4.1 Study design and research settings 
 
This study was carried out at the Helsinki University Hospital (HUH) 
Abdominal Center during 2015–2020. The Abdominal Center and 
Department of Transplant and Liver surgery functions as a secondary and 
tertiary referral unit for 1.2 and 1.9 million inhabitants, respectively. As the 
largest hepatobiliary center in Finland, the Department of Transplant and 
Liver surgery offers a referral center to the whole country.  
 
Study I was a randomized clinical trial. Study II was a retrospective, case–
control cohort study. Studies III and IV were retrospective; in addition, 
Study IV was a population-based study. The HUH institutional review board 
approved all studies. Studies I and II were approved by the HUH ethical 
board and Studies II and IV by the Finnish Institute for Health and Welfare. 





This thesis included 2338 patients with benign gallbladder disease and 294 
patients diagnosed with gallbladder malignancy. All patients with benign 
gallbladder disease were operated on in the HUH Abdominal Center (Study 
I and III) or Department of Transplant and Liver Surgery (Study II). Study 
IV included all GBC patients treated at FICAN (National Cancer Center 
Finland) South. 
 
Study I. This randomized controlled single-blinded trial was carried out at 
the Surgical Hospital (until December 2015) and Jorvi Hospital (from 
January 2016) day surgery unit between February 2015 and April 2017. 
Patients were referred to the HUH Abdominal Center for elective LCC and 
were assessed for eligibility for this trial. Patients were excluded if a surgeon 
had an inappropriate level of experience (< 5 previous operations) with 3D 
laparoscopy if another operation was planned to be performed 
simultaneously, or the risk of conversion was estimated to be high. 
Altogether, 209 patients were randomized to either the 2D or 3D arm. 
Patients were blinded to their randomization group. All 15 surgeons who 
participated in this study were tested for stereo acuity with the Randot® 
Stereotest (Stereo Optical, Chicago, Illinois, USA). Patients were contacted 




Study II. 52 patients with major BDI were identified from a prospectively 
maintained database at the HUH Department of Transplant and Liver 
surgery. Patients were treated at this clinic during 2000–2016. For these 
patients, to compare the QOL between patients with and without BDI, 
controls were searched for from hospital patient databases by matching 
them on age (up to a 10-year difference), sex, the date (up to 3-month 
difference) and urgency of an operation. All patients with BDI and controls 
were contacted by sending three questionnaires (GIQLI – gastrointestinal 
QOL index, SF-36 – Short Form Health Survey and an additional non-
validated questionnaire including information on education, working 
status, opinion of the provided information before the LCC and possible 
discomfort and medications after the primary operation).  
 
Study III. All patients whose gallbladder had been removed for benign 
reasons were included in the study. These patients were operated on in the 
Surgical Hospital, Meilahti Hospital, Jorvi Hospital, and Peijas Hospital 
from November 2010 to May 2012. Patients were identified from the 
electronic patient database by procedure codes JKA20 and JKA21, for open 
and laparoscopic cholecystectomy, respectively. Altogether, 2034 patients 
were included.   
 
Study IV. This retrospective population-based study included all patients 
with GBC diagnosed in the FICAN South area. Patients with GBC were 
gathered from the Finnish Cancer Register (FCR). After exclusion, 294 
patients with GBC were found between 2006–2017. The 12-year period was 
divided into 3 equal periods to be able to see any changes in incidence, 
survival or treatment patterns. Follow-up data were available for 291 




3D Laparoscopic cholecystectomy in Study I was conducted with a 
Wolf® 2D/3D laparoscopic HD (high-definition) device. In this, a non-
deflectable 30° 10-mm scope was used. The surgeon was standing on the 
patient’s left side, and the monitor was on the right. The surgeon and 
assistant wore passive polarized glasses to perceive a 3D-view. The assistant 
was standing on the surgeon’s left. The surgeon was allowed to switch to a 
2D mode during, for example, trocar insertion, if needed. The standard 
laparoscopic four-port technique was used in starting the preparation from 
the neck of the gallbladder and aiming at CVS. The gallbladder was removed 
from its' bed, and a plastic bag was used to remove the gallbladder from the 
abdominal cavity. The operation time was calculated from the incision to 
wound closure.  
Conventional laparoscopic cholecystectomy is the gold-standard 
procedure for cholecystectomy. The four-port technique was used in all LCC 
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of this thesis. In Study I, the instrument was standardized, and therefore a 
Wolf® 2D/3D laparoscopic HD devise was used. Since the system can 
display 2D and 3D views, it was switched to 2D mode during this 
randomization. Surgeons did not wear polarizing glasses during a 2D 
operation. They were also not allowed to switch on the 3D position. 
Otherwise, the operation was accomplished as described above.   
 
Converted cholecystectomy was used if the surgeon considered an open 
procedure safer than continuing with the laparoscopic technique. In this, 
laparoscopic instrumentation is removed and proceeded with an open 
technique. An open cholecystectomy was described earlier in section 2.3 
Gallbladder surgery. 
 
Hepaticojejunostomy was performed with the Roux-en-Y technique. In 
this, the small bowel was divided, and the jejunum lifted close to the liver 
hilum and sutured end-to-side with the bile duct(s) (Figure 5 A). An 
enteroanastomosis between the disconnected proximal jejunum and the 
middle or distal part of the jejunum (jejunojejunostomy) was performed. 
 
Patency delineates as an open biliary tree after surgical reconstruction. By 
definition, a bile duct then appears without the need for stents or 
manifested episodes of jaundice or cholangitis (156).  
 
Index treatment is the first surgical reconstruction that was attempted to 
restore the biliary tree continuity (156). In this, the procedure was either an 
end-to-end anastomosis between the proximal and distal bile duct or a 
hepaticojejunostomy. The salvage procedure, for example, with a 
laparotomy and drainage, meant an additional operation designed to create 
favorable conditions for future reconstructive procedures. 
 
Primary and secondary patency was defined as an open biliary tract 
after surgical reconstruction. The primary patency was achieved if the 
patient did not need any further operation or was free from stents and 
drainages after 90 days from primary index treatment. If the patient 
achieved and maintained the primary patency after that, the result was 
graded as a grade A result. However, if the patient could not achieve or 
maintain the primary patency, the result was defined as grades B, C, or D, 
depending on whether the patient was able to obtain the secondary patency 
(156).  
 
The actuarial primary patency rate represents the grade A result after 
the biliary reconstruction of BDI  (156). It is calculated as a Kaplan–Meier 
curve and can visualize the patency rate’s change as a function of time. The 
actuarial secondary patency rate is the same as the aforementioned Kaplan–
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Meier curve, but is calculated for patients undergoing a secondary bile duct 
repair. 
 
Lymphadenectomy included lymph nodes around the choledochus, 
hepatic artery, and liver hilum.  
 
Liver resection was performed in cases where the BDI was associated 
with significant vascular injury, which had damaged the liver. In the 
extended cholecystectomy or the re-resection after incidental GBC, a wedge 
resection or sections IV and V was performed with a possible concomitant 
lymphadenectomy. 
 
4.4 Statistical methods 
 
All data extracted from an electronic database or directly from patients 
(Studies I and II) were collected and analyzed with Statistical Package for 
the Social Sciences (SPSS Statistics ver. 22–24 IBM, Armonk, NY, USA). To 
reveal possible changes in the GBC incidence (Study IV), R statistical 
software including Epi and epitools packages was used. 
 
Study I. A two-tailed power analysis was performed by using 80% power, 
0.05 alpha. Ten minute differences between the 2D and 3D groups was 
considered clinically significant. Patients were randomized with a 1:1 
allocation to either group. The CONSORT flowchart can be found in the 
original article. Differences between groups with continuous variables were 
tested with the Mann–Whitney U test and categorical variables with 
Fisher's exact test. P values <0.05 were considered statistically significant. 
 
Study II. Newly proposed standards for reporting the outcome after biliary 
reconstruction were used (Cho 2018). The terms ‘patency,’ ‘actuarial 
primary patency,’ ‘primary and secondary patency,’ and ‘index treatment’ 
are defined above following these standards. Kaplan–Meier analysis was 
used to calculate the actuarial primary patency rate at 1-, 3-, and 5-years 
follow-up and actuarial secondary patency rate at one year and end of 
follow-up. A log-rank test was used to compare groups. If the patient died 
before an index treatment was possible, the patency could not be calculated. 
Differences between groups with continuous variables were tested with the 
Mann–Whitney U test and categorical variables with the Fisher’s exact test 
or Chi-square. P-values <0.05 were considered statistically significant. 
 
Study III. The FCR was used to crosscheck patients whose gallbladder was 
not sent to histopathologic examination, verifying that no GBC was missed 




Study IV. Survival estimates after GBC diagnosis were based on Kaplan–
Meier analysis. Groups were compared with the log-rank test. Differences 
between groups with continuous variables were tested with the Mann–
Whitney U test and categorical variables with Fisher’s exact test. P-values 
<0.05 were considered statistically significant. To determine the change in 
the incidence of GBC, crude incidence rates (IR) were calculated. Further, 
the crude and age-adjusted incidence rate ratios (IRR) and their 95% 
confidence intervals (CI) were assessed from the Poisson models without 







As shown in Table 9, this thesis included 2444 patients operated on 
primarily for a benign reason, mainly for symptomatic cholecystolithiasis 
(61.1%). Patients with incidental GBC in Study IV were significantly older (p 
< 0.001) than in the other studies. Study IV patients were also operated on 
more often (47.9% vs. 23.8%) for acute cholecystitis than in Study III which 
included all patients operated on for primarily benign reasons within 1.6 
years. Additionally, Study IV included 195 patients diagnosed with GBC by 
imaging or at autopsy (n=21). 
 
Table 9 Basic characteristics of all patients for whom gallbladder was 
primarily operated on for benign reasons. *ten patients with an incidental 
GBC; **35% of Study IV population. Abbreviations: IQR – Interquartile 
range 
 Study I Study II Study III Study IV 
N 105+104 52+ 53 2034* 103** 




53 (41-64.6) 72.9 (65.4-
81.1) 









































































































5.1 Comparison of 3D and 2D laparoscopy in cholecystectomy (I) 
 
Basic demographics. The study included 105 patients randomized to the 
3D arm and 104 patients to the 2D arm. The median age was 48.5 years, and 
the median body mass index (BMI) was 27.8. There were no differences 
between 3D and 2D groups according to basic characteristics. The primary 
operative characteristics of all patients in this study are provided in Table 5. 
The patients were mainly healthy women (72.2%) with an American Society 
of Anesthesiologists’ (ASA) physical status classification score of 1–2 in 
92.4%, and a Charlson’s comorbidity index (CCI) score of 0 in 53.1%. The 
indication for LCC was predominantly symptomatic gallstone disease 
(94.7%). Three attendings and 12 residents operated on patients. 
Stereoacuity was perfect (10) in 6 surgeons, who performed operations on 
154 (73.7%) patients. 
 
Operation time was the primary outcome measure. The overall average 
operation time was 48 min. For residents, this was 61 min, and for 
attendings 42 minutes. One operation was converted to open in the 3D 
group. The operation time did not differ between 3D and 2D groups (49 min 
vs. 48 min, p=0.703), nor did it differ by subgroup analysis including 
subgroups by surgeon status (attendings: 42.5 min vs. 42 min, p=0.703; 
residents: 62 min vs. 60 min, p=0.596), 3D or LCC experience, resident 
surgeon’s gender or stereovision, or patients’ BMI.  
 
Complications during and 30-days after the operation were evaluated. 
Intraoperative complications occurred in 29 (13.9%) patients. These 
complications were minor (gallbladder rupture or intraoperative bleeding 
managed with diathermy or hemostatic). No bile duct injuries occurred. 
Postoperative complications were reported using the Clavien-Dindo 
classification (CDi). A total of 43 (22.5%) patients out of 191 patients, who 
responded to 30-day contact for follow-up, had a CDi I–II complication. No 
other postoperative complications occurred. Neither postoperative nor 
intraoperative complications differed between the 3D and 2D groups. 
 
5.2 Biliary tract injuries (II) 
 
Basic demographics. The study included 52 patients with a major 
(Strasberg E) BDI and 53 patients with an uneventful cholecystectomy who 
responded adequately to questionnaires. Their basic characteristics are 
combined in Table 5. Briefly, the median age of patients with BDI was 53 
years, and 57.7% (n=30) were women. Patients with BDI were operated on 
for symptomatic gallstone disease in half of the cases (n=26). Seven (13.5%) 
patients with BDI had had an acute cholecystitis, and in a quarter (n=13), 
the patient had had cholecystitis earlier. The operation was emergent in ten 
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(19.2%) of patients with BDI. Except for one operation, all were initially 
laparoscopic, but in 30 (57.4%) cases were converted to open.  
 
5.2.1 Surgical reconstruction after bile duct injury 
 
The BDI was detected intraoperatively in 29 (55.8%) cases. Patients with 
BDI most often had Strasberg type E1 BDI with distributions detailed in 
Table 10. BDIs were further graded into subgroups, according to Cho et al. 
(2018), where Strasberg type E1–3 BDI belongs to Grade 2 and types E4 and 
E5 to Grade 3 (Figure 5). 
 














Damage detection Intraoperative 
1st – 2nd POD 






Damage repair Immediate 
Early (1st-14th POD) 












Table 10. Detailed information of the BDI and the repair. Abbreviations: 
BDI – Bile duct injury; POD – post-operative day; HB – hepatobiliary  
 
The primary patency rate at one year was 43.5%, 65%, and 77.8% if the index 
treatment was performed immediately, during the first two weeks or later, 
respectively (Figure 10). The estimated primary patency rates were similarly 
43.5%, 59.6%, and 77.8% at three years. The actuarial long-term primary 
patency after 1, 3, and 5 years was 83%, 80%, 76% for repairs by the 






























Figure 10. Primary patency for patients with primary repair performed 
immediately, between 1-14 days postoperatively or over two weeks after the 





















Figure 11. Primary patency for patients treated primarily by hepatobiliary 
(HB) surgeon (dark grey) and all patients with Strasberg type E bile duct 




Primary repair by 
HB-surgeon 
All BDI-patients   
35                   29                     27                   25                   22                   22 
52                   30                     28                   26                   23                   23 
0                   1                    2                   3                   4                   5 





Immediate repair  
1st-14th POD 
After 15th POD   
0                  1                 2                  3                 4                  5 
       Years 
23                   10                  9                    9                   8                   8 
20                   13                 12                  11                 10                 10 









5.2.2 Quality of life after bile duct injury  
 
At the time of this study, 46 patients with BDI were alive; 35 (75%) patients 
responded to questionnaires. The median follow-up was 90 months. 
Women responded to these surveys more often than men (71.4%, n=25). For 
the BDI-patients who responded (n=35), matched controls (n=103) were 
identified and sent questionnaires, and 53 (51%) returned adequately filled-
in questionnaires. Patients who responded had similar educational 
(p=0.226) and working (p=0.25) statuses. Patients who did not have a BDI 
were more often satisfied with preoperatively provided information about 
risks (22 vs. 7; 41.5% vs. 20%; p=0.025)  
 
When the QOL was tested with GIQLI and SF-36 questionnaires by each 
grade (A–D) of patency, it did not differ when compared with controls 
(Figure 12). The BDI did not appear to be different between BDI patients 
and controls overall (Figure 13; A), nor did it differ with respect to the 
obtained patency (Figure 13; B).  
 
Figure 12. Quality of life after uncomplicated cholecystectomy (Controls) and BDI 
reconstruction by the BDI grading (A–D) in median 90 months (IQR 69.7–116.0) 
follow-up. (Median (IQR) PCS: Controls 53.4 (46.8–57.7), Grade A 51.7 (43.6–
57.6), Grade B 57.8 (41.0–60.6), Grade C 41.4 (35.8–51.1), Grade D 57.0 (42.0–
60.5). Median (IQR) MCS: Controls 53.4 (45.2–56.6), Grade A 54.4 (40.7–57.2), 
Grade B 55.6 (51.1–57.4), Grade C 48.6 (39.3–61.0), Grade D 48.4 (40.0–52.6). 
Median (IQR) GIQLI: Controls 123 (105.0–129.5), Grade A 108 (83.5–131.5), 
Grade B 124 (107.0–129.0), Grade C 105 (80.5–125.5), Grade D 108.5 (81.0–
130.0)). Abbreviations: BDI – bile duct injury; PCS – Physical component 
summary; MCS – Mental component summary; GIQLI - gastrointestinal quality-




Figure 13. Quality of life after repair of a major BDI and uncomplicated 
cholecystectomy (Controls) (A) (Median PCS 51.7 vs. 53.4; MCS 53.3 vs. 53.4; 
GIQLI 109.0 vs. 123.0) and when the patency was achieved and maintained or lost 
or not achieved (B) (PCS 51.7 vs. 50.6; MCS 54.4 vs. 551.7; GIQLI 108.0 vs. 111.5). 
Abbreviations: BDI – bile duct injury; PCS – Physical component summary; MCS 









5.3 Necessity of histopathological examination after 
cholecystectomy (III) 
 
Macroscopic findings. The basic demographics are listed in Table 
5. Surgeons indicated that most of gallbladders removed for benign reasons 
were normal (n=1464; 70%). An obvious tumor was seen in 4 (0.2%), a 
polyp in 6 (0.3%), and a thickened or necrotic wall in 505 (24.8%) samples. 
Of 118 gallbladders not sent to HPE, 6 displayed thickened or necrotic walls. 
These patients were crosschecked with the FCR, and no GBC was found. 
 
Microscopic findings. HPE was performed for 1916 (94%) specimens. 
Minor dysplasia was apparent in 20 (1%) and major dysplasia in 3 (0.2%) 
samples. Ten samples showed a GBC, almost all (90%) had 
adenocarcinoma. Each of these gallbladders had an abnormal wall on 
macroscopic examination. 
 
Patients with GBC. Of 2034 patients, 10 (0.5%) patients had an 
incidental GBC. Seven patients were women. The median age was 74 years; 
one patient was 49 years old. Each patient underwent some imaging (US 
n=9, CT n=1, magnetic resonance imaging (MRI) n=3) and was diagnosed 
with either a gallstone disease (n=6) or acute cholecystitis (n=4). None of 
them were suspected to have a malignancy. After the operation, a tumor was 
seen in three, a local hardness in one, a thickened wall in five, and acute 
cholecystitis in one specimen. Five patients were able to proceed to the liver 
resection. Three of these patients were alive and disease-free at the end of 
follow-up. An estimated survival for patients diagnosed with an incidental 

















Figure 14. Kaplan–Meier curve for survival for patients with incidental 
GBC in Study III 
0              0.5               1               1.5              2               2.5               3 
                 Years 








5.4 Incidence and management of gallbladder 
malignancy (IV) 
 
Incidence. During the 12-year study period, 273 patients were treated for 
GBC and 21 were diagnosed at autopsy. Patient medical records were 
available for 270 patients. The crude overall incidence of GBC in the FICAN 
south was 1.32/100,000 inhabitants. The crude GBC incidences were 1.50, 
1.28, and 1.18/100,000 inhabitants at periods A, B, and C, respectively. 
Comparing age-adjusted IRRs of periods B and C to period A, a decrease in 
the incidence appeared (age-adjusted IRR 0.95, 95% CI 0.92-0.98; 
p=0.010) 
 
Treatment. Of 294 patients with GBC, 103 cancers (35%) were detected 
after primary cholecystectomy. These patients were often older (>70 years) 
and operated on for acute cholecystitis than in Studies I–III (Table 5). The 
treatment changed during the three study periods; the number of patients 
treated with any surgical procedure increased over time (Period A N=29, 
30.9%; Period B N=44, 50.6%; Period C N=46, 51.7%, p=0.006). Similarly, 
the number of patients receiving only the best supportive care decreased 
(Period A N=41, 44.7%; Period B N=26, 29.9%; Period C N=24, 27.0%, 
p=0.039). However, the number of patients proceeding to curative-intent 
surgery did not change (N=14, 14.9%; N=18, 20.7%; N=19, 21.3%; p=0.3). 
 
A simple cholecystectomy was a curative operation for four patients (pT0-
1N0M0). After primary cholecystectomy, the curative intent operation was 
performed for 31 out of 103 (30.1%) patients. The reoperation was 
complementary lymphadenectomy (n=2), liver bed resection with 
lymphadenectomy (n=18), or liver bed resection with lymphadenectomy 
and incision resection (n=11). The direct curative-intent operation was 
performed for 16 (5.5%) patients: extended cholecystectomy (n=8) 
combined with bile duct resection (n=2), simple cholecystectomy and liver 
bed resection (n=2), or lymphadenectomy (n=2), or bile duct resection 
(n=1), or bile duct resection and lymphadenectomy (n=1). 
 
Gemcitabine (n=15) was the most often used adjuvant therapy after 
curative-intent surgery. Additionally, patients were treated with 
capecitabine (n=4) and combination chemotherapy (n=1). Moreover, one 
(1.5%) patient received radiotherapy. Patients who did not proceed to a 
curative-intent surgical procedure were treated with gemcitabine (n=75), 
capecitabine (n=5), and combination chemotherapy (n=5), but also 
received radiation therapy (n=3). Five (1.9%) patients were treated with a 
combination of chemoradiation. During the three study periods, no changes 
in treatment patterns with curative-intent procedures or oncologic therapy 




Survival. The prognosis of GBC has not improved during the 12-year study 
period. Kaplan–Meier curves for survival among all patients, patients with 
curative-intent resection, and patients who did not proceed to curative 
resection but received chemo- or radiation therapy, are shown in Figures 
13–15. Further, the estimated 1-, 3-, and 5-year survivals are in Tables 11–
13, divided in three periods. The estimated overall 1- and 5-year survival for 









Figure 15. Kaplan–Meier curve for 








Figure 16. Kaplan–Meier curve for 




Table 12. Estimated overall survival for 
patients with curative-intent resection 
 
 
Figure 17. Kaplan–Meier curve for 
overall survival among patients with 




Table 13. Estimated overall survival for 
patients with palliative chemotherapy 
  
Survival, % Period A Period B Period C 
95% CI 126.7-223.3 161.7-330.3 158.0-310.2 
1-year 32.0% 37.9% 39.3% 
3-year 13.4% 18.4% 18.9% 
5-year 9.3% 17.2% 14.2% 
Survival, % Period A Period B Period C 
95% CI N/A N/A N/A 
1-year 85.7% 88.9% 89.5% 
3-year 71.4% 72.2% 63.6% 
5-year 57.1% 61.1% 50.9% 
Survival, % Period A Period B Period C 
95% CI 163.1-240.9 224.1-487.9 152.9-355.2 
1-year 28.6% 44.8% 39.3% 
3-year 0% 3.4% 7.1% 





6.1 Three-dimensional view in laparoscopic cholecystectomy 
 
In Study I, we showed that 3D laparoscopy is not safer or more efficient than 
2D laparoscopy in cholecystectomy. Hanna et al. and Currò et al. were also 
unable to demonstrate the superiority of 3D laparoscopy in terms of speed 
or safety (95, 113). For nearly four decades, surgeons have performed 
procedures laparoscopically, most commonly by removing the appendix or 
gallbladder. It is understandable that the three-dimensional visibility is not 
superior to the customary two-dimensionality in such operations where, for 
example, suturing is not needed. However, in potentially technically 
demanding procedures, such as radical prostatectomy, mini gastric bypass, 
laparoscopic inguinal hernia repair (TAPP), and splenic hilar 
lymphadenectomy, the benefits of 3D technology are reflected in increased 
safety or efficacy (105, 109, 240, 241). We can assume that the 3D view 
improves the depth perception in such a way that in procedures that require 
these features, the benefits of this 3D technology become apparent, thereby 
accelerating the procedure and reducing errors, making operations safer. 
 
Although the operation time as a primary outcome measure did not differ 
between groups, the surgeons were nearly 100% satisfied with the 3D 
laparoscopic view. This has also been the result of previous studies, albeit 
from two decades ago, when 3D technology was still evolving (95). The loss 
of binocular vision in the 2D laparoscopy can increase errors by impairing 
hand–eye coordination and eliminating depth perception. As described 
earlier, a large proportion of biliary complications is due to misperception 
of biliary structures. However, we were not able to show differences in 
complication rates between 3D or 2D LCC. Fortunately, major BDIs are rare 
and no lesions appeared in this study. It does not seem advisable to use a 
3D laparoscope for LCC based on this study, given the cost of 3D technology, 
the current size of the optics (10 mm), and the limited surgical benefit. 
 
6.2 Bile duct injury in laparoscopic cholecystectomy 
 
Current guidelines suggest LCC for the treatment of symptomatic gallstone 
disease, including also most patients with complicated gallstone disease (7, 
78). Chronic cholecystitis increases the possibility of BDI by causing 
difficult adhesions and changes the structure of the gallbladder wall. Even 
in non-inflamed circumstances, a BDI is possible due to the many 
anatomical variations. In Study II, half of the patients with a major BDI were 
operated on electively for symptomatic cholelithiasis. The other patients 
had a variety of conditions requiring urgent care. A small proportion of 
these injuries could have been avoided if conservative treatment had 
evaluated possible. Conservative treatment for acute calculous cholecystitis 
Discussion
 65 
is indeed a treatment of choice in elderly patients deemed unfit for surgery 
(80). However, an even more restrained line has been highlighted in a 
systematic review that suggests conservative treatment even for patients 
with mild disease. Only a small proportion of these patients go on to develop 
symptomatic gallstone disease after mild inflammation, which could justify 
a more restrictive strategy (242). 
 
Even without complications, up to 40% of patients who undergo surgery for 
typical symptoms of cholelithiasis may remain symptomatic (243, 244). 
Persistent pain after uncomplicated LCC increases healthcare costs and 
patient concerns for their own well-being (244). Van Dijk et al. conducted a 
multicenter trial to study whether a restricted strategy was efficient in 
decreasing the number of LCCs in patients with uncomplicated 
symptomatic gallstone disease and to reduce pain after LCC (245). Though 
they were not able to show a difference in pain reduction between study 
groups after LCC, they did find a lower number of cholecystectomies in the 
restrictive strategy group. In our study (I), after a short 30-day follow-up 
13% of patients reported pain that affected normal life. This does not 
indicate an incorrect patient selection assuming the pain decreases over 
time in a longer follow-up. Consequently, as in our Study II, patients with a 
major BDI had an equal QOL compared to patients with uneventful 
cholecystectomy, suggesting that QOL may even after a major complication 
normalize in long-term follow-up (11). However, QOL is very multifactorial 
and the effects of a BDI on QOL is still not clear (12, 142, 246-249).   
 
As shown in various previous studies, we noted better results after primary 
reconstruction of a major BDI when the reconstruction was performed by a 
hepatobiliary surgeon (143, 144). Comparison between hepato-biliary 
centers has been difficult when lacking a systematic and uniform reporting 
system for biliary reconstructions. In 2018, Cho’s and Strasberg’s group 
published a recommendation according to which we also reported the 
results of our BDI repairs (156). We found three other clinics where this 
reporting system was used, in Mexico and South Africa. The primary 
patency was achieved in 83 to 100% in these studies (152-154). In our Study 
II, the primary patency rate for patients operated primarily by an HB 
surgeon was 83% but actuarial primary patency at 36 months follow-up 
decreased to 80%. Since this study also included patients referred from 
other centers after primary treatment had failed, the overall actuarial 
primary patency was 58% at 1-year follow-up. It should be noted that the 
number or results of patients who have successfully undergone biliary 
reconstruction in other surgical units in Finland were not considered in this 
study. 
 
Notable is that the highest primary patency rate was achieved with a robot-
assisted technique (follow-up 16 months) in the Mexican highly detailed 
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retrospective study (152). The BDI repair has traditionally been performed 
with an open technique, but previous results also make laparoscopic lesion 
repair something to be considered but only under conditions that are 
favorable and when the technique is controlled (152, 250). A recent meta-
analysis draws a cautious conclusion in favor of delayed repair. Better 
results may be achieved with a favorable level of nutrition, the possibility to 
diagnose a simultaneous vascular injury and by reducing major 
inflammation (251). As seen in Figure 8, the ‘actuarial primary patency’ was 
higher in patients treated on a delayed schedule. However, it should be 
noted that in this dataset, a third (N=17) of patients had undergone the 
index treatment prior to referral. Therefore, no far-reaching conclusions 
can be drawn in this regard.  
 
6.3 Examination of removed gallbladder  
 
GBC is a very rare malignancy that has a highly variable incidence between 
countries. The routine HPE has been justified by a poor overall prognosis 
and a better prognosis in early detected GBC (13, 16, 195). On the other 
hand, iGBC has an even lower incidence varying between 0.17–0.5%, 
making HPE an unnecessary resource utilization for most of the samples 
(252, 253). Therefore, routine HPE can be questioned (254).  
 
Similarly, Talreja et al. or Tayeb et al. did not find gallbladders with GBC 
that had a normal wall in macroscopic evaluation (255, 256). However, as 
the policy changes, one could question the clinician’s ability to assess 
abnormal mucosal changes (195). It is more likely that when the routine 
manner is removed, the clinician’s threshold for a referral will be lowered 
for even the slightest suspicious change, and no GBC is missed (254, 256). 
On the other hand, in Study III, 70% of samples were evaluated as normal 
by the surgeon, but only 60% by the pathologist. It is the case that the 
surgeon’s method of reporting an abnormality (such as cholesterolosis) 
interpreted in such a retrospective manner may differ significantly from the 
pathologist’s method.  
 
Resource utilization is one of the main subjects of concern in modern 
medicine. The cost–benefit of HPE of the gallbladder specimen has recently 
been studied in several clinics in the Netherlands (17, 18, 257). Savings from 
selective gallbladder HPE are estimated at 1.6 million EUR, and in Finland, 
the same action would produce an estimated 0.5 million EUR in savings per 
year. Based on Study III results, we recommended selective HPE to the 
HUH operational units. By this, only gallbladders with an inflamed 






6.4 Management of gallbladder cancer 
 
Study IV demonstrates that GBC’s incidence has decreased in Finland but 
not in the same way at different ages. A more detailed analysis in Study IV 
suggested that GBC’s age-standardized incidence in those over 50 and 
under 70 years of age has been declining since 2006. Changes in lifestyle 
and in the metropolitan population due to migration from other parts of 
Finland and from abroad may contribute to this relative decline. However, 
our study period and study population were relatively low, but an absolute 
reduction of 6.8 cases per million person-years was still detected. 
 
In a SEER-database-based study, the number of GBC patients doubled after 
the start of the current millennium (169). The changes in the treatment of 
symptomatic gallstones may partly explain the difference in the number of 
GBCs diagnosed in studies in which the study period staddles both 
millennia. When MIS established its place in the treatment of gallstone 
disease, LCCs became the treatment of choice. It is possible that the change 
in the diagnostics and achievability of a cholecystectomy increased the 
incidence of GBC. However, if the gallbladder is removed earlier, cancer 
does not even develop, which would cause a decline in the incidence. In 
Study IV, all GBC cases were diagnosed during the era of MIS, and only a 
third of diagnoses were established after cholecystectomy, so other reasons 
for the GBC incidence decline undoubtedly exist. We could speculate on the 
impact of lifestyle changes, migration, or healthcare changes, but our Study 
IV provides no insight into these. 
 
As earlier mentioned, surgical resection is the only possibility for curative 
treatment of GBC. However, the rate of resections varies greatly in different 
studies. In India, the resection rate was reported to be 20%, in the 
Netherlands 23%, in Sweden 37%, in Canada 46%, and in the United States 
overall 55% (169, 173, 258-260). In our study, the resection rate was 19%. 
Such large variability is likely to be explained by varying research settings, 
but differences in treatment practices between countries need to be 
considered. For instance, patients with a stage over T1a GBC treated only 
with simple cholecystectomy were included in the resected patients in the 
Swedish study (258).  
 
The studies from the Netherlands and the United States did not specify the 
type of resection, and indeed, in the American database, the overall 5-year 
survival only reached 13% despite the high resection rate (169, 259). Thus, 
it could be suspected that all patients treated with a simple cholecystectomy 
alone were also included in the resections in the American study. In the 
Canadian study, the high resection rate resulted in a 25% 5-year OS 
compared to 12% in our study (260).  Dixon et al. found that a more 
aggressive approach to GBC surgery increased 5-year survival fivefold (217). 
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Therefore, it may be that a more open-minded evaluation of patients with 
GBC should be considered. Another retrospective study revealed that even 
with residual disease appearance in the re-exploration, the survival benefit 
is apparent after complete R0 re-resection (215). 
 
An aggressive increase of resections and neoadjuvant therapy for selected 
patients with GBC could result in better outcomes. The majority (63%) of 
patients with GBC in Study IV were at stage IIIB or beyond, possibly the one 
reason for the low resection rate. However, neoadjuvant therapy was not 
used during the study period. According to the systematic review of Hakeem 
et al., neoadjuvant therapy could be beneficial for 66% of patients with stage 
IIIA or greater (227). However, not all patients necessarily proceed to a 
curative-intent procedure. 
 
After the BILCAP study, biliary tract cancer treatment recommendations 
included adjuvant chemotherapy with capecitabine (228, 230). Although 
only a small proportion of this heterogeneous population with biliary tract 
cancers in the BILCAP study were GBC patients, a per-protocol analysis 
showed a 17-month improvement in survival. Our study included patients 
before the BILCAP study, and only four patients received capecitabine 
adjuvant therapy. However, the adjuvant therapy was offered for 21 patients 
of 51 resected patients (simple cholecystectomy was sufficient for 4 
patients). On the other hand, these patients were more often at an advanced 
stage and had significantly reduced 5-year survivals than other resected 
patients. 
 
6.5 Strengths and limitations 
 
Study I showed that the 3D laparoscopic system could not provide clear 
benefits in LCC compared to the 2D system. This is one of the largest RCT 
cohorts considering 3D and 2D laparoscopic surgery in cholecystectomy. 
However, this study included only the patients undergoing elective 
cholecystectomy and who were eligible for day surgery. Since the severe 
complications of LCC are rare, it is, however, unlikely that the research 
setting in more difficult conditions would make a difference in the 
appearance of complications in 3D or 2D surgery.  
 
QOL after BDI is widely studied, but our Study II was able to dive deeper 
and compare QOL between patients who achieved patency with different 
levels and the controls. The study group consisted only of patients with 
major E-type BDI and their controls, which makes the study population 
more uniform but, at the same time, limits the generalizability of the results. 
Furthermore, the study group’s limited size may restrict the result of the 
QOL questionnaires. Not to mention, possible selection among patients 
with uncomplicated cholecystectomy should also be considered. Thus, with 
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the moderately small data (n = 53, 51% of the respondents), we cannot 
completely rule out the role of chance. In the long-term follow-up, the 
changes in patients’ perception after a severe illness or complication may 
affect how some physical changes reflect on their experience of life quality 
(11, 12). The QOL may be affected by patients’ shift in perspective, often 
referred to as reconceptualization (261). Encountering a severe disease 
might change a person’s values and expectations differently from a 
condition perceived as benign. 
 
In Study II, we used a recently standardized reporting system for BDI that 
can later contribute significantly to the possibilities to compare results from 
different centers. Our result of patency is comparable with other centers 
who published their results using the BDI repair with an open technique.  
 
Studies III and IV were purely retrospective, which may limit the accuracy 
of the data. The larger retrospective data was in Study III, which despite of 
the study design, was able to demonstrate the redundancy of HPE in 
macroscopically normal gallbladders. Patients whose gallbladder was not 
sent to HPE were crosschecked from the FCR for possible developed 
malignancy. Thus, we were able to safely recommend that only 
macroscopically aberrant gallbladders should be sent for HPE. 
 
There are no other population-based studies considering GBC in Finland 
other than our Study IV. The study period was as wide as possible to have 
enough patients and still have available medical records. However, since the 
GBC is (fortunately) rare, only 270 patients with GBC were available and the 
study might be underpowered to show changes in some variables. Although 
the FCR is considered to have good accuracy, under-reporting, according to 
a Swedish study, may occur, especially in connection with biliary tract 
cancers (262). Besides, especially in locally advanced GBC, reported cancer 
might be interpreted as originating from the bile duct, gallbladder, or liver, 
causing miss-reporting. However, such a change as in the Swedish study's 
reporting activity hardly occurred in our 12-year Study IV period, and the 
observed decrease in incidence is genuine.  
 
6.6 Future prospects 
 
Gallstone disease is undoubtedly one of the conditions that is an increasing 
burden to healthcare. As recommended, an operative approach to 
symptomatic cholecystolithiasis is currently the most common treatment. 
Given the potential for surgical complications and the potential for 
persistent symptoms after surgery, patients most likely to benefit from LCC 




This same problem of increasing gallstone disease is also associated with the 
possibility of increased GBC. However, this does not seem to be the case in 
Southern Finland. Despite this, the treatment results have not improved. 
This cancer with poor prognosis should be studied both nationwide and in 
multicenter studies to possibly identify key factors for survival in order to 





7 CONCLUSIONS   
 




The three-dimensional laparoscopic technique does not improve the 
efficacy or safety of LCC in the elective day-surgery;  
 
Study II 
With the appearance of a major BDI, immediate consultation with a 
hepatobiliary surgeon is recommended to obtain a favorable repair 
result. However, even with this significant complication, the QOL is equal 
after uncomplicated LCC in long-term follow-up; 
 
Study III  
Macroscopically normal gallbladders that have been operated on during 
normal circumstances do not need a histopathologic examination to 
confirm the benign finding of the gallbladder wall; 
 
Study IV  
The incidence of GBC has decreased in southern Finland. Although 
surgical and oncological treatment in GBC patients has increased, patient 
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